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ABSTRACT 
Apoptosis is a specialized, active form of cell death that is important in both health and 
disease.  It is responsible for maintaining regulated development and tissue homeostasis and 
participates in the elimination of aged, damaged, or displaced cells.  Apoptosis is also an 
inherent tumor suppressive mechanism, and the ability of cancer cells to evade death is widely 
acknowledged as one of the hallmarks of cancer development.  In tumor cell populations, 
disruptions in apoptosis commonly occur through modulation of key players in the apoptotic 
cascade.  The central role of capsase-3 as an executioner of apoptosis makes it an ideal drug 
target for circumventing such upstream disruptions and restoring effective apoptosis in cancer 
cells.  This work investigates the use of PAC-1, a newly developed procaspase-3 activating 
compound, in the treatment of canine osteosarcoma.  Procaspase-3 is expressed in 
osteosarcoma cells, and furthermore, greater expression is seen in malignant canine 
osteoblasts than normal osteoblasts.  Exposing cells to PAC-1 results in the activation of 
procaspase-3 to caspase-3, increased caspase-3 catalytic activity, and induction of apoptosis in 
osteosarcoma cells.  The greatest degree of activity is seen after 48 hours of exposure to the 
PAC-1.  Additionally, a large proportion of spontaneous primary and metastatic tumors express 
procaspase-3 to a varying degree, and the pattern of expression appears to be conserved within 
patients from primary to metastatic lesions.  In conclusion, the study’s findings support future 
investigation of PAC-1 as a personalized anticancer treatment strategy for osteosarcoma. 
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CHAPTER 1 
INTRODUCTION 
 
 Osteosarcoma (OS) is the most common primary bone tumor of dogs, and it is estimated 
that 10,000 dogs and 1,000 children per year develop OS in the United States.  Osteosarcoma is 
a high grade, aggressive neoplasm whose behavior closely parallels pediatric OS in humans.  
Morbidity results from pain and decreased limb function as a result of focal skeletal osteolysis 
and tumor extension from the medullary canal.  Currently, both aggressive and palliative 
treatments directed at the primary tumor are limited by patient and owner specific 
considerations.  Additionally, despite aggressive treatment with surgical resection and adjuvant 
chemotherapy, most dogs will eventually go on to die of metastatic disease.  Characterization 
of new molecular targets has the potential to lead to the development of novel anti-cancer 
strategies that could result in better treatment outcomes for dogs and people with OS. 
 Chapter 2 opens by providing an overview of apoptosis and its general role as a hallmark 
of cancer development.  It begins to set the stage by discussing how restoration of effective 
apoptosis may be a platform for development of new anti-cancer drugs.  The next section of 
chapter 2 introduces the most crucial members of the apoptotic program—caspases.  Caspases, 
a family of cysteine proteases, are the specialized cellular machinery which propels the cascade 
of events leading to cell death.  This section details the structure and varied roles of caspases as 
initiators or executioners.  It discusses in detail the pathways that lead to caspase activation 
and the players involved in regulating these pathways.  The third section of chapter 3 discusses 
the role of apoptosis in tumorigenesis and specifically highlights caspase-3 in cancer.  Because 
caspase-3 activation is a pivotal and common endpoint of apoptotic pathways, it is an ideal 
target for circumventing acquired upstream disruptions in apoptosis.  Neoplastic cells have 
been shown to sequester caspase-3 in its inactive form, and thus, therapies that focus on 
activating caspase-3 are a promising novel anti-cancer strategy.  PAC-1, the first procaspase 
activating compound, is a small molecule activator of caspase-3 that produces apoptosis of 
neoplastic cells in vitro.  Chapter 2 concludes by discussing the advantages and disadvantages of 
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local treatment strategies currently available for canine OS, and the rationale for investigating 
PAC-1 as new local treatment for OS. 
 In order to justify the use of PAC-1 in OS, we first sought to identify the target 
procaspase-3 in osteosarcoma cells.  Chapter 3 identifies the presence of procaspase-3 in 
canine, murine, and human osteosarcoma cell lines.  It then investigates the effects of exposure 
of osteosarcoma cells to PAC-1 in vitro.  When osteosarcoma cells were exposed to low, 
biologically relevant concentrations of PAC-1, conversion of the target to active caspase-3 was 
documented.  Additionally, PAC-1 caused an increase in caspase-3 catalytic activity and induced 
apoptosis in canine osteosarcoma cells in a dose and time dependent fashion.  These findings 
are encouraging, and warrant further investigation of PAC-1 as a treatment for canine OS. 
Although procaspase-3 was identified in osteosarcoma cells in vitro, it was important to 
determine whether the target was also present in spontaneously occurring primary and 
metastatic canine OS as well.  Additionally, we sought to ascertain if malignant osteoblasts had 
increased expression of the target over normal osteoblasts. Chapter 4 reports on the 
differential expression between malignant and normal canine osteoblasts.  Furthermore, it 
describes the variation in expression of procaspase-3 in spontaneously occurring tumors.  The 
data highlights procaspase-3 as a viable drug target in canine OS and lends justification for the 
use of PAC-1 as a personalized anticancer strategy, especially in cases where prescreening 
procaspase-3 concentrations are found to be high. 
Chapter 5 concludes this manuscript by summarizing the author’s findings and discusses 
future strategies for the clinical application of PAC-1 as a treatment for canine OS.   
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CHAPTER 2 
LITERATURE REVIEW 
 
2.1 Apoptosis, an overview. 
Apoptosis or programmed cell death is an innate physiologic process that is indispensable 
for the maintenance of regulated development and tissue homeostasis.  It plays a vital role in 
the elimination of damaged or displaced cells and cells lacking the appropriate signals for 
survival, thus allowing the body to actively determine if and when cells should die [1-4].  In 
contrast, dysregulated apoptosis has been implicated in the development of many pathologic 
conditions, including neurodegenerative disorders, autoimmune diseases, sepsis and 
particularly, cancer [1, 3-6].  It is now widely acknowledged that evasion of apoptosis is one of 
the hallmarks of cancer development [3, 4, 7, 8], and naturally, this discovery has led to a 
diverse array of scientific explorations into the mechanisms by which apoptosis is disrupted in 
(or inhibited by) tumor cell populations.  With such questions at the forefront of cancer 
research, the last ten years has brought a wealth of continually emerging insight into the 
mechanisms by which programmed cell death is executed.  The eventual hope is to use this 
knowledge to identify drug targets and develop compounds that might effectively treat cancer 
through restoration of the apoptotic program [9-11]. 
 In order to begin to identify potential therapeutics that might re-sensitize cancer cells to 
apoptosis, a detailed understanding of the apoptotic process and machinery is required.  
Apoptosis is a specialized form of cell death, which is distinguished from its counterpart, 
necrosis, by distinct morphological changes, including membrane blebbing, cytoskeletal 
disruption, nuclear pyknosis, chromatin condensation and genomic fragmentation [1-5, 12, 13].  
This ordered process of cellular disassembly allows for the formation of membrane-enclosed 
vesicles or apoptotic bodies, which are subsequently engulfed by neighboring phagocytic cells 
without provoking an inflammatory response [2, 3, 7, 14] (Figure 2.1).  Induction of apoptosis 
may be promoted through a variety of external and internal pro-apoptotic stimuli; and in 
mammals, is initiated via two principle pathways: (1) the extrinsic pathway through ligation of 
death receptors and (2) the intrinsic pathway by way of cellular stress and mitochondrial 
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release of cytochrome c [4-8, 12, 15, 16].  However, regardless of the pathway to cellular 
suicide, all routes converge to share a key and central component—the activation of caspases 
[5, 6, 8, 12, 15, 17].  Caspases, a family of cellular proteases, are the specialized cellular 
machinery which propels the cascade of events leading to cellular death.  Understanding these 
vitally important enzymes and the factors which regulate their activation is fundamental for the  
derivation of strategies to manipulate apoptosis for therapeutic gain [6, 8, 10, 15, 17]. 
 
2.2 Caspases 
 Caspases were implicated as a central feature of apoptosis in 1993 when the C. elegans 
ced-3 gene was demonstrated to encode a cysteine protease analogous to interleukin-1-β-
converting enzyme (ICE) in mammals [18, 19].  Overexpression of ICE, which was subsequently 
renamed caspase-1, was then shown to be adequate for the induction of apoptosis within 
mammalian cells [19, 20].  These seminal breakthroughs suggested that mammalian caspases 
may possess crucial apoptotic functions similar to that of the ced-3 gene product, and thus, set 
in motion the characterization of the mammalian caspases.  Currently, 14 caspases are 
identified in mammals of which caspase-1 through -10 and caspase-14 are found in humans [5, 
8, 21, 22].  Caspase-11 and -12 are murine homologues of human caspase-4 and -5, and 
caspase-13 is a bovine homologue of human caspase-4 [5, 8, 23].  While not all caspases are 
necessary for apoptosis or solely capable of those functions [24, 25]; within the context of 
apoptosis, these powerful proteases act as both initiators and effectors of cellular dismantling 
[5, 15, 17, 22]. 
 
2.2.1 Caspase Structure 
 Caspases are potent cysteine proteases whose functions are tightly linked to their 
structural makeup [5, 8].  Generally speaking, there is a great deal of similarity among caspases 
with regards to their amino acid sequence, structure, and the predominant requirement for 
cleavage of substrates after an aspartic acid residue (Asp) [1, 17, 26, 27].  Caspases contain 
three structural domains, including an N-terminal prodomain and two conserved catalytic 
domains, which are comprised of a large subunit (20 kDa) and a small subunit (10 kDa) (Figure 
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2.2 A).  Additionally, in a number of family members, a linker region is present to connect the 
catalytic subunits [5, 17, 28].  These unstructured regions are often the focus of 
(auto)proteolysis during maturation or, in some cases, activation [29].  Importantly, cleavage 
sites within these regions contain Asp residues, emphasizing the ability of caspases to auto-
activate or become activated by other caspases as part of the amplification cascade [1].   
 Caspases, in accordance with other proteolytic enzyme systems, are synthesized as 
inactive proenzymes (zymogens).  Because unregulated caspase activity would be lethal to the 
cell, these latent precursors (procaspases) require conversion to their active form via distinct 
conformational changes [30].  Active caspases exist as obligate dimers of identical catalytic 
units, each composed of one large and one small subunit and containing one active amino acid 
recognition site (total of two active sites in the proteolytic dimer) [31, 32] (Figure 2.2 B.).  Based 
on crystal structure and studies with synthetic peptide libraries, it has been established that all 
caspases bind their substrates with similar substrate pockets (S1, S2, S3, and S4) [33, 34].  While 
both the large and small subunits donate residues to form the binding cleft, it appears that the 
major factors that determine substrate specificity are located within the small subunit [34].  
Initially, it was thought that all caspases were activated by proteolysis [27], but over the last 
few years, overwhelming evidence has surfaced that this is only one mechanism responsible for 
caspase activation (principally pertaining to the executioner caspases) [30, 32].  It appears that 
while the structures of all active caspases are largely the same, the mechanism of 
transformation from the inactive to active form varies greatly between initiators and 
executioners [29] (Figure 2.2 B). 
 
2.2.2 Caspase classification: initiators versus executioners 
 While several classification schemes have been described, this discussion will focus on 
distinguishing caspases by their function and position within apoptotic signaling pathways: 
either as initiators or executioners (effectors) of apoptosis.  This method of classification 
emphasizes key differences in structure, function, activation, and substrate specificity.  
Discussion of the inflammatory caspases (caspases-1, -5, and -4) will not be included as it is 
outside the scope of this review. 
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Initiator Caspases 
The importance of caspase structure is highlighted when we consider the different roles 
of the proapoptotic caspases.  Initiator caspases (procaspase-2, -8, -9, -10) are characterized by 
long prodomains, containing special motifs such as death effector domains (DED, procaspase-8, 
-10) or caspase recruitment domains (CARD, procaspase-9) that are critical for their activation 
in vivo [3, 8, 12, 30] (Figure 2.3).  In the inactive state, initiator procaspases exist as monomers 
within the cell and require dimerization to undergo activation, a process recently discovered to 
be independent of cleavage [35-37] (Figure 2.2 B).  Dimerization is facilitated by recruitment of 
initiator caspases to adapter molecules, resulting in high local concentrations.  Adaptor 
molecules are part of larger oligomeric activation assemblies within the cell that convene 
following an apoptotic signal [29, 30, 38, 39].  The DED and CARD are responsible for mediating 
the homophilic interactions (e.g. CARD-CARD and DED-DED) between procaspases and their 
adaptor proteins (e.g. APAF-1 with procaspase-9; FADD with procaspase-8), and thus, directing 
them to their specific activation platforms (e.g. DISC with caspases-8, -10 and apoptosome with 
caspases-9) [29, 30, 38, 39].  Initiator caspases, as their name implies, generally respond to 
upstream cellular signals in order to set the apoptotic cascade in motion.  Their inherent 
narrow substrate specificity allows them to recognize and activate their downstream targets—
the executioner caspases [30, 40].  
  
Executioner caspases 
 The apoptotic executioner caspases (procaspase-3, -6, -7) are characterized by short 
prodomains (Figure 2.3) and occur constitutively as inert homodimers [36].  The role of this 
short N-terminal prodomain has yet to be clearly defined; however, it seems that its purpose 
relates to the efficiency of activation of executioners in vivo, perhaps due to sequestration or 
cellular compartmentalization [41, 42].  The proteolytic activity of inactive executioners is 
restrained by a short linker region, and during activation, cleavage at specific Asp residues 
divides the amino acid chain into its small and large catalytic subunits [29, 31, 32] (Figure 2.2 B).  
The crystal structures of zymogen and active caspase-7 provide the greatest evidence 
elucidating the process of catalytic groove formation during activation [43, 44].  Processing of 
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the linker region allows re-ordering of catalytic and substrate binding residues via mobile loops, 
and consequently, formation and stabilization of the active site is achieved [29, 30, 32].  As 
alluded to earlier, cleavage is carried out under most circumstances by an initiator caspase, but 
this may also occur in limited cases by the serine protease granzyme B [29, 33].  Once activated, 
the apoptotic executioners are collectively responsible for the degradation of many cellular 
substrates that bring about the characteristic morphologic changes known as apoptosis [3, 5, 6, 
8, 30].  
  
2.3 Caspase activation pathways 
As previously mentioned, initiator caspases require some form of signal for a cell to be targeted 
for destruction.  The origin of this message, from either the soup of extracellular signaling 
molecules or from variations within the intracellular environment, determines the pathway of 
caspase activation.  There are two main, distinct but convergent pathways that trigger 
apoptosis within the cell—the extrinsic and the intrinsic pathways [3-5, 32, 45].  The extrinsic 
pathway, also known as the “death receptor pathway”, is initiated by engagement of death 
receptors at the cell surface [39, 46].  Conversely, the intrinsic pathway, otherwise known as 
the “mitochondrial pathway,” is triggered by mitochondrial membrane changes and the release 
of cytochrome c [47-49]. 
 
2.3.1 The Death Receptor Pathway (Extrinsic) 
 The extrinsic pathway plays a vital role in the physiological regulation of apoptosis (e.g. 
immune system education, tumor immunosurveillance), and dysregulation has been implicated 
in the pathogenesis of cancer and disorders of the immune system [50-55].  Stimulation of the 
extrinsic pathway is initiated by ligand-bound death receptors (DR) of the tumor necrosis factor 
receptor superfamily (TNFR), chiefly TNF-TNFR-1, FasL-Fas, and TRAIL (TNF-related apoptosis-
inducing ligand/APO2)-DR4 or –DR5 [39, 52, 56, 57].  These death receptors are type I 
transmembrane proteins, which are characterized by cysteine rich extracellular domains (CRDs) 
that facilitate ligand binding and cytoplasmic interaction domains such as the death domain 
(DD) [46, 57, 58].  Of the members of the TNF-receptor family, the Fas and TRAIL (DR4 and DR5) 
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receptor-mediated signaling paths are best understood with regards to induction of apoptosis.    
Both Fas and TRAIL are alike in that ligation of receptors induces the formation of the death 
inducing signaling complex (DISC), which subsequently recruits and activates the initiator 
procaspase-8 [57, 59] (Figure 2.4).  Interestingly, caspase-10 may also be recruited to the DISC, 
but its action alone is not sufficient to induce apoptosis and its physiologic role remains 
ambiguous [60, 61]. 
 
Ligation of death receptors and the DISC 
 Signal transduction begins when trimerization of receptors within the cell membrane 
brings the intracellular domains in close proximity with one another [46, 62].  Previously, it was 
believed that trimerization was the result of ligand binding in a trimeric form; however, the 
discovery of preassembled receptor clusters on the cell surface challenged this notion [52, 63, 
64].  Preassembly has since been shown to occur as a result of a region termed the preligand 
assembly domain (PLAD), which resides within the death receptors’ extracellular domain [65-
67].  The PLAD plays a critical role in the efficiency of ligand binding and consequently receptor 
activation [67].  Following ligation, an activating conformational change takes place within the 
receptors to cause recruitment of the adaptor proteins, Fas associated death domain (FADD) or 
TNF-receptor associated protein with death domain (TRADD).  The adaptor proteins act, exactly 
as the name denotes, to link the extracellular signal (DR ligation) to an intracellular effect 
(caspase activation).  These adaptor proteins interact with the death receptors through 
homologous death domains (DDs) present on both molecules and similarly, with the initiator 
caspases via corresponding death effector domains (DEDs) [46, 52, 57].   
 The ensuing aggregate of proteins is known as the DISC and sets the apoptotic cascade 
in motion starting with activation of caspase-8 by dimerization [68] (see section 2.2.2).  Active 
caspase-8 goes on to cleave caspase-3, which in turn, leads to cell death [69].  As is typical of 
many biological systems, the extrinsic pathway is not completely independent of the intrinsic 
pathway and some degree of “cross-talk” between the two occurs.  Caspase-8 also cleaves Bid, 
a BH3-only member of the Bcl-2 family of proteins, to truncated Bid (tBid), causing changes in 
mitochondrial membrane permeability and subsequent release of cytochrome c and 
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Smac/DIABLO [70-72].  This cross stimulation of the intrinsic pathway drives the activation of 
caspase-9 which in turn cleaves caspase-3.  In addition to cellular degradation, caspase-3 
activates caspase-8, completing a positive feedback loop that amplifies the apoptotic cascade 
[53, 73] (Figure 2.4). 
 
Regulators of the extrinsic pathway 
 Notably, several proteins serve to negatively regulate the death receptor pathway at 
various levels including: decoy receptors, FLICE-inhibitory proteins (c-FLIP), and inhibitors of 
apoptosis proteins (IAPs) [74].  The decoy receptors (DR-1, -2, -3 and osteoprotegerin [OPG]) 
are similar to Fas and DR-4/-5 in their extracellular domains but have truncated or absent death 
domains rendering them incapable of transmitting an apoptotic signal [39, 74-78].  
Consequently, competition for FasL/TRAIL binding through decoy receptor expression may work 
to inhibit ligand-induced apoptosis [52, 77, 79].  Further downstream, c-FLIP (long [c-FLIPL], 
short [c-FLIPS], and Raji B-cell line derived [c-FLIPR] isoforms [80]) acts to regulate recruitment 
and activation of the initiator caspases at the DISC [81, 82].  All c-FLIP variants contain two DEDs 
and can associate with FADD by way of DED-DED interactions, but only c-FLIPL additionally 
contains a caspase-like domain [80, 82] (Figure 2.5).  While it is widely accepted that c-FLIPS and 
c-FLIPR inhibit death receptor-mediated apoptosis by vying for binding to FADD [46, 82, 83], the 
function of c-FLIPL has long been controversial [84].  Only recently, a clear dual pro- and anti-
apoptotic role for c-FLIPL has been established that appears to depend on the c-FLIPL to 
caspase-8 concentration ratio [83, 85].  The role of the IAP proteins will be discussed in detail in 
section 2.4.  Briefly, with regards to the extrinsic pathway, IAPs bind and inhibit procaspase-3, 
thus arresting the cascade of proteolysis and preventing Fas/caspase-8 induced apoptosis [86-
88]. 
   
2.3.2 The Mitochondrial Pathway (Intrinsic) 
 The intrinsic pathway is triggered principally in response to internal cellular stimuli such 
as cytokine deprivation, cytotoxic stress, and DNA damage (e.g. ionizing radiation and 
chemotherapeutic drugs) [32, 47, 89].  The focal point of the pathway is the mitochondria, and 
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advancement through it revolves around a key event—mitochondrial outer membrane 
permeabilization (MOMP) [52, 57, 89, 90].  During MOMP, various pro-apoptotic proteins, 
sequestered in the intermembrane space, such as cytochrome c and Smac/DIABLO, acquire 
access to other proteins in the cytosol where they promote caspase activation and apoptosis 
[89, 91-94] (Figure 2.6).  In order to clearly comprehend this event, a cursory understanding of 
mitochondrial structure, function and the factors that regulate them is required. 
  
Mitochondria 
  Mitochondria are the metabolic hub of the cell, and are best known for their role in 
conversion of dietary nutrients to cellular energy (ATP) through oxidative phosphorylation [90, 
95, 96].  Their ability to perform this function relies on the selective permeability of the 
mitochondrial membranes.  The mitochondrial inner membrane (MIM) is normally 
impermeable to protons and other ions, and this barrier is vital to maintaining transmembrane 
potential and energy transduction [97-99].  Conversely, the mitochondrial outer membrane 
(MOM) is permeable to small molecules but impermeable to proteins, which is critical for cell 
survival [96, 98, 99].  Disruptions in the MIM and MOM may be produced by multiple 
mechanisms [100, 101]; however, strong evidence points to the Bcl-2 family of proteins, 
particularly Bax and Bak, as the central regulators of MOMP relevant to apoptotic cell death 
[96, 102, 103].  Intriguingly, we will see that ATP is not only an absolute requirement for life but 
also for energy-dependent cell death, emphasizing that the MIM must be left intact during the 
apoptotic program [104-106]. 
   
Bcl-2 Family Proteins 
 The Bcl-2 (B-cell lymphoma-2) family proteins are the key controllers of the 
mitochondrial pathway, and it is the balance between the members’ opposing activities that 
determine the ultimate fate of the cell [107].  Classically, three groups of Bcl-2 family members 
are recognized that share up to four homology domains (BH1-BH4): the pro-apoptotic group 
(Bax, Bak), the anti-apoptotic group (Bcl-2, Bcl-XL), and the BH3-only group (Bad, Bid, Bim, 
NOXA, PUMA) [3, 52, 107, 108].  As alluded to earlier, members of the first group, Bax and Bak, 
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commit the cell to apoptosis by mediating MOMP.  Activated Bax translocates to the MOM 
where activated Bak is already incorporated [109, 110].  Within the MOM, Bax and Bak are 
thought to undergo conformational changes and form homo-oligomers preceding apoptosis 
[111, 112].  While the precise mechanism of MOMP execution remains controversial, one 
model proposes that Bax and Bak oligomers form pores through which intermembrane proteins 
can pass, thus allowing cytochrome c efflux to the cytoplasm [107, 113].   
 Conversely, the anti-apoptotic Bcl-2 family members protect the cell from apoptosis and 
guard mitochondrial integrity.  Bcl-2 is an integral MOM protein in all cells and Bcl-XL associates 
with the MOM in many cell types, usually after an apoptotic signal [114-116].  Localization at 
the MOM allows Bcl-2/Bcl-XL to sequester and/or inhibit pro-apoptotic counterparts thereby 
preventing release of cytochrome c [3, 107, 116-118].   
The last group, activated BH3-only proteins, promote apoptosis via interactions with 
each of the core groups of Bcl-2 family proteins [119].  Certain BH3-only proteins (Bid, PUMA, 
Bad, NOXA) appear to antagonize prosurvival members, whereas others (Bid and Bim) have 
been shown to directly activate Bax and Bak [119-121].  Two competing models exist regarding 
the relative importance of these interactions.  Briefly, the derepression model suggests that 
BH3-only proteins must antagonize the steady inhibitory binding of Bcl-XL to Bax/Bak that 
usually prevents MOMP [116, 122, 123].  Alternatively, the direct activation model suggests 
that Bcl-XL acts as a sponge, sequestering BH3-only proteins that are direct activators of 
Bax/Bak (e.g. Bid).  In order to cause activation, these proteins must be freed by other BH3-only 
members via interactions with Bcl-XL [113, 119, 124]. 
 
The apoptosome—“wheel of death”   
 Following MOMP, cytochrome c release into the cytoplasm leads to the assembly of the 
caspase activating complex of the intrinsic pathway—the apoptosome [125, 126].  Cytochrome 
c complexes with the adaptor protein Apaf-1 (apoptotic protease activating factor-1), which 
leads to a conformational change and permits exposure of its N-terminal CARD and greatly 
enhances dATP/ATP binding activity [91, 125].  This binding triggers formation of a seven-
spoked wheel, often called the “wheel of death,” which in turn recruits procaspase-9 into its 
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central hub via CARD-CARD interactions [91, 125] (Figure 2.7).  Procaspase-9 is then 
transformed to its active form and can go on to activate downstream caspases-3 and -7 to 
execute cell death [127]. 
 
2.3.3 The Common Pathway: Caspase-3 in the spotlight 
 Both the extrinsic and the intrinsic pathways converge upon a common pathway—
activation of executioner caspases.  Named for their role in cleaving the major cellular 
substrates during apoptosis, the executioner caspases are vital for producing cell death and 
amplifying the apoptotic signal [33, 128, 129].  The three executioner caspases-3, -6, and -7 are 
highly homologous to one another [130], but caspase-3 is the most extensively studied, and 
thus, its role in apoptosis is more clearly defined [8, 130].  Analysis of apoptosis in cells of 
caspase-3 knockout animals showed inhibition of certain morphological hallmarks  (membrane 
blebbing, DNA degradation, nuclear fragmentation) but retention of others (nuclear 
condensation, phosphatidylserine exposure) [130, 131].  Similarly in a cell-free apoptotic 
system, depletion of caspase-3, but not caspase-6 or caspase-7, resulted in hindrance of many 
downstream events of apoptosis, such as various substrate cleavages and DNA fragmentation 
[8, 130, 132].  These findings suggest that caspase-3 may be the most important effector of 
cellular destruction, but likely does not fully control all aspects of apoptosis [130].  One 
explanation for this is that caspase-6 and -7 may play specific roles in more minor pathways 
that activate executioner caspases such as endoplasmic reticulum (ER) stress [33, 133, 134]. 
 The substrates of the effector caspases are numerous and include: cytoplasmic proteins 
(e.g. actin, β-catenin), nuclear proteins (e.g. laminin-A/B, nuclear mitotic apparatus protein), 
DNA metabolism/ repair proteins (e.g. PARP, DNA-topoisomerases, RNA-polymerase), protein 
kinases (e.g. PKC , MAPK, ERK, Akt)  signal transduction pathway proteins (e.g. pro-interleukin 
cytokines, phospholipases), cell cycle/cell proliferative proteins (e.g. p21, p27, pRB), apoptosis 
related proteins (e.g.Bcl-2, Bcl-XL, ICAD), and more [33, 34, 135-137].  Proteolytic cleavage of 
this vast array of substrates is believed to result in a variety of cellular consequences, many of 
which contribute to the signature changes observed during apoptosis [138].  Among these, one 
of the best characterized examples is the degradation of nuclear DNA through caspase-
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mediated activity of CAD (caspase activated DNase).  Caspase-3 cleaves ICAD (inhibitor of 
caspase-3-activated DNase) inside the nucleus releasing CAD [139-142].  Thereafter, CAD forms 
a homodimer and cuts double stranded DNA precisely at nucleosomal linkers [143, 144].  This 
process occurs early in apoptosis, fragmenting DNA and swiftly halting DNA replication and 
transcription. 
 
2.4 Inhibitors of Apoptosis (and IAP inhibitors) 
Most cell regulatory pathways include a system of checks and balances, and apoptosis is 
no exception.  Caspases are powerful killers that irrevocably enact cellular suicide, and thus, 
healthy cells must have a way to prevent unwanted activation of these enzymes.  Inhibitors of 
apoptosis proteins (IAPs) are a family of structurally alike proteins that restrain caspase activity 
under conditions favoring cell survival [145, 146].  They are characterized by 1-3 novel domains 
of 70-80 amino acids called the baculoviral IAP repeat (BIR) [27, 147, 148], and to date, eight 
mammalian members have been identified [NAIP (neuronal apoptosis inhibitory protein), c-
IAP1, c-IAP2, Survivin, XIAP (cross-linked IAP), Bruce/Apollon, ILP-2 (IAP-like protein-2), and 
Livin/ML-IAP (melanoma IAP)] [145].  The IAP’s BIR domains are zinc-chelating fingers that 
directly bind specific caspases and allow obstruction of caspase catalytic grooves by BIR linkers 
[3, 33].  Generally speaking, the IAPs that contain multiple BIRs, such as XIAP, utilize the BIR1-
BIR2 linker to impede caspase-3 and -7 and the BIR3 to inhibit caspase-9 [3, 88, 125, 149] 
(Figure 2.8).  When cellular conditions shift towards those favoring apoptosis, inhibition of 
caspases must be relieved.  This additional tier of control is accomplished by Smac (second 
mitochondria-derived activator of caspases)/DIABLO, which along with cytochrome c, is 
released from the mitochondria during MOMP to antagonize IAPs and promote apoptosis [27, 
74, 92, 150]. 
 
2.5 P53 in Apoptosis 
 P53  is undoubtedly one of the most famous of the tumor suppressors due to the fact 
that it is functionally impaired in the vast majority of human tumors [151].  It is a highly 
complex, multifunctional protein that acts as a crucial responder to a variety of stress signals 
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encountered during malignant transformation and progression, for example genotoxic damage, 
oncogene activation, loss of normal cell contacts, and hypoxia [152, 153].  The central 
mechanism of p53’s anticancer activity has been attributed to its ability to induce apoptosis, 
and it does so in both a transcriptional-dependent and independent manner [57, 153, 154].  As 
a transcription factor, p53 stimulates expression of a number of pro-apoptotic gene products 
involved in the mitochondrial pathway, such as Bax, PUMA, NOXA, and Apaf-1, and represses 
other anti-apoptotic gene products such as Bcl-XL and survivin [153, 155-158].  In the death 
receptor pathway, it induces Fas expression in certain tissues [159] and activates TRAIL 
receptor DR5 in response to DNA damage [160, 161].  Aside from transcriptional activation and 
repression, p53 provokes apoptosis in a transcriptional-independent manner via direct 
interactions with MOMP inducers at the level of the mitochondria [154, 162-164].  While the 
details of this mechanism are still emerging, p53 appears to cause Bax and Bak oligomerization 
at the MOM and antagonize anti-apoptotic actions of Bcl-2 and Bcl-XL through physical 
interactions [156, 165]. 
 
2.6 Apoptosis in Tumorigenesis 
 Acquired resistance to apoptosis is one of the hallmarks of all types of cancer, and over 
50% of neoplasms display defects specifically in their apoptotic machinery [3, 4, 7, 8, 52].  
Moreover, such defects may confer tumor cells resistance to many of the anti-cancer therapies 
currently in use.  Disruptions of both the extrinsic and intrinsic pathways may be involved in 
tumorigenesis and, in general, this can occur either via inactivation/downregulation of pro-
apoptotic elements or overactivation/upregulation of anti-apoptotic elements [166-168].   
 Within the extrinsic pathway, evasion of death receptor signaling may occur by 
decreased receptor expression or inactivation.  For example, downregulation of Fas (CD95) is 
observed in hepatocellular carcinomas, neoplastic colon epithelium, melanomas, and drug-
resistant leukemias [169-173]; and CD95 gene mutations have been reported in hematological 
malignancies as well as a variety of solid tumors [174-178].  Additionally, deletions or mutations 
in TRAIL receptors, resulting in a loss of both copies, have been demonstrated in a small 
proportion of some cancers, such as osteosarcoma and breast carcinoma [179, 180].  A second 
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mechanism to evade death receptor induced apoptosis is aberrant expression of decoy 
receptors.  In glioblastomas and some carcinomas, overexpression or genetic amplification of 
decoy receptors has been identified [181, 182] and may help predict stage in gastric carcinoma 
[183].  Aside from interfering with death receptors, signal transduction through the extrinsic 
pathway can be blocked at the level of the DISC.  One strategy seen in carcinomas is 
overexpression of c-FLIP, resulting in competitive inhibition of procaspase-8 recruitment at the 
FADD [184].  Furthermore, caspase-8 may be impaired by genetic or epigenetic mechanisms. 
Alternative splicing of caspase-8 mRNA in leukemia and neuroblastoma generates caspase-8L, a 
variant lacking the catalytic site [185, 186].  Also, caspase-8 inactivation can be achieved via 
hypermethylation of regulatory gene sequences in various pediatric tumors (e.g. 
rhabdomyosarcoma, medulloblastoma, and retinoblastoma) [187, 188].   
 Within the intrinsic pathway, MOMP may be impeded by abnormal expression of anti-
apoptotic Bcl-2 family proteins or inactivation of Bax or BH3-only proteins.  One well 
documented example is overexpression of Bcl-2 in human follicular lymphoma, caused by 
translocation of the bcl-2 gene onto the immunoglobulin gene locus [189, 190].  In addition, 
mutated Bax, either via nucleotide substitutions or frameshift mutations has been identified in 
colon cancer as well as hematopoietic malignancies [191, 192].  Caspase-9 inactivation is 
another theoretical mechanism by which cancer cells may evade apoptosis.  Strong evidence 
demonstrating an association between caspase-9 mutations and cancer risk is currently 
minimal; however, some studies have reported that certain gene polymorphisms were 
associated with a significantly increased risk of lung cancer [8, 193].  Finally, aberrant 
expression of inhibitor of apoptosis proteins may also confer tumor cells resistance to 
apoptosis.  A notable example of this is deregulation of survivin.  Survivin, in contrast to its low 
or undetectable expression in most normal human adult tissues, was found to be expressed at 
high levels in the majority of cancers [194] and predicted an unfavorable prognosis in 
neuroblastomas, acute myeloid leukemia, and non-Hodgkin lymphoma [195-197]. 
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2.6.1 Caspase-3 in Cancer 
 Since both intrinsic and extrinsic apoptotic pathways lead to the common pathway, any 
upstream disruption in apoptosis causing inefficient effector caspase activation may be 
hypothesized to lead to increased concentrations of the inactive procaspase-3 within tumor 
cells.  Indeed, cells from certain cancer cell lines and cancerous tissues have been confirmed to 
have elevated procaspase-3 concentrations when compared with noncancerous controls.  
Recently, the National Cancer Institute performed a systematic evaluation of 60 cell lines and 
found that concentrations of procaspase-3 varied from undetectable to greatly elevated, 
particularly in lung, melanoma, renal and breast cancers [198].  In addition, a study evaluating 
isolates from individuals with colon cancer demonstrated a six-fold average elevation when 
compared to nearby noncancerous tissue controls [199].  Other notable examples of elevated 
procaspase-3 expression include a proportion of neuroblastomas [200], lymphomas [201], 
leukemias [202], hepatocellular carcinomas [203], and melanomas [204].  Moreover, 
procaspase-3 elevation appears to be clinically relevant in certain tumors.  In one study of 
patients with acute myeloid leukemia, a high level of uncleaved caspase-3 was correlated with a 
significantly decreased survival, whereas, a high level of cleaved caspase-3 denoted an 
improved survival [202]. 
 Aside from procaspase-3 sequestration, caspase-3 mutations may occasionally occur in 
tumors.  Mutated caspase-3 has been reported in the MCF-7 breast cancer cell line [205].  Also, 
in one report by Soung et al which investigated caspase-3 mutations in various cancers, a small 
proportion of colon cancers and one case each of lung, stomach adenocarcinoma, 
hepatocellular carcinoma, and multiple myeloma were found to have a mutated caspase-3 
gene.  These mutations were concluded to have arisen somatically, and consisted of 6 missense 
mutations either involving the large (17kD) or small (12kD) protease subunit.  The remainder of 
the mutations were silent or in non-coding or untranslated regions [206].  Another study 
evaluating squamous cell carcinoma of the head and neck (SCCHN) detected an association 
between certain caspase-3 polymorphisms and increased risk of SCCHN, suggesting a possible 
role of caspase-3 mutations in tumorigenesis [207]. 
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2.7 PAC-1 
Induction of apoptosis has recently been recognized as a powerful anticancer strategy.  
Because caspase-3 activation is a common end-point of all activating pathways, it may be an 
ideally suited target for circumventing many possible upstream disruptions of apoptosis.  
Furthermore, evidence of procaspase-3 elevation in cancer cells in combination with the 
relative infrequency of inactivating caspase-3 mutations suggests that pharmacological caspase-
3 activation may be an effective strategy to direct apoptosis within tumor cells.  In 2006, a 
novel small molecule called PAC-1 was identified as the first procaspase activating compound 
from a library of structurally diverse small molecules screened in vitro [208].  PAC-1 
preferentially activated procaspase-3 in a dose- and time-dependent fashion as assessed by 
caspase-3 substrate cleavage activity and western blotting.  PAC-1 also demonstrated powerful 
proapoptotic effects, such as phosphatidylserine exposure, chromatin condensation, PARP-1 
cleavage, and cellular blebbing.  These effects were observed in cancer cell lines in a manner 
strongly correlated with procaspase-3 concentrations [208].  Additionally, promising anticancer 
properties were observed in primary colon cancer isolates and mouse xenograft models as a 
result of direct activation of procaspase-3.  Conversely, noncancerous cell types were less 
susceptible to the proapoptotic effects of PAC-1, suggesting a degree of selectivity for cancer 
cells [208].  In 2009, Peterson et al. elucidated the mechanism of action of PAC-1 in vitro; PAC-1 
activates procaspase-3 through the sequestration of inhibitory zinc ions, allowing procaspase-3 
to autoactivate itself to caspase-3.  These investigators demonstrated that the catalytic activity 
of procaspase-3 is inhibited by zinc and that PAC-1 binds strongly to zinc, relieving this 
inhibition (Figure 2.9).  They hypothesized that once caspase-3 is generated, it can activate 
more procaspase-3, causing caspase-3 substrate cleavage and apoptosis [209].  In further work, 
they showed that fluorescently labeled PAC-1 co-localizes with sites of caspase-3 activity in 
cancer cells, bolstering the evidence supporting a direct mechanism of action for PAC-1 [210]. 
 An in vivo study by Lucas et al. investigating the pharmacokinetics of PAC-1 in healthy 
dogs has been recently reported [211].  The purpose of this research was to evaluate whether 
concentrations and exposure durations of PAC-1 shown to induce cytotoxicity in lymphoma cell 
lines in vitro were achievable in healthy dogs through a constant rate infusion (CRI) intravenous 
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delivery strategy.  The investigators concluded that the oral bioavailability of PAC-1 was 
variable and relatively low, but that maintenance of predicted steady state concentrations in 
normal dogs was safely attained via intravenous CRI lasting for 24 or 48 hours in duration.  
Using a pharmacologically derived dosing regimen in 4 healthy dogs, plasma concentrations of 
10.7 ± 2.0 μM were achieved after 6 hours of infusion and steadily maintained to 36 hours 
[211]. 
 
2.8  Canine Osteosarcoma 
 Osteosarcoma (OS) is the most common primary bone tumor of dogs, accounting for 
approximately 85% of malignancies arising in the skeleton [212-215].  It is a high grade, 
biologically aggressive neoplasm of mesenchymal origin that closely parallels human OS [216].  
It is estimated that 10,000 dogs and 1,000 children per year develop OS in the United States 
[214, 217, 218]; the majority of children diagnosed are in their second decade of life [216].  The 
peak incidence of canine OS occurs primarily in middle-aged to older animals, with a median 
age of 7 years; although, a bimodal age distribution is reported with a second small peak at 18 
to 24 months [219].  Approximately 75% of OS occurs in the appendicular skeleton [213, 220].  
Analogous to humans, the metaphysis of long bones is the most common primary location, with 
the forelimbs affected twice as commonly as the rear limbs [221].  The most frequent 
anatomical sites are the distal radius (35%) and proximal humerus (18%) followed by the distal 
femur, proximal tibia, and distal tibia [213, 221].  Osteosarcoma is typically a cancer of large 
and giant breed dogs with only 5% of tumors occurring in dogs weighing less than 15 kilograms, 
the majority of which originate in the axial skeleton [222].  The precise etiology of both canine 
and human OS is unknown.  Genetic predispositions have been documented in humans, such as 
Li-Fraumeni, Rothmund-Thomson and Bloom syndromes, and suspected in dogs, based on 
breed and size prevalence [214, 216].  Additionally, exposure to ionizing radiation and sustained 
microtrauma (ex. repetitive weight bearing stresses, metallic implants) has been proposed as 
possible risk factors in dogs for OS development [223-227].   
 Canine OS is a locally aggressive and invasive neoplasm that causes osteolysis, aberrant 
bone production, or both processes concurrently [214].  Dogs affected with appendicular OS 
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typically present with progressive lameness and a firm swelling at the primary site.  Pain can be 
a significant problem and is likely induced by disruption of the periosteum due to lysis of 
cortical bone and tumor extension from the medullary canal [214].  Pathologic fracture may 
occur and is usually associated with acute non-weight-bearing lameness [228].  The pulmonary 
parenchyma is the most frequent site of metastasis [219], and  regrettably, despite local 
control, most dogs (90%) will go on to eventually die of metastatic disease [213, 229]. 
   
2.8.1 Current Local Therapy for Osteosarcoma  
 The local effects of OS have a significant impact on patient mobility and quality of life, 
and thus, addressing the primary tumor is one of the major goals of OS therapy.  Effective local 
therapy for canine OS necessitates the removal or killing of malignant osteoblasts [214] and 
various treatment modalities have been employed to this end.  Additionally in the palliative 
setting, therapies aimed at counteracting local consequences, such as malignant osteolysis and 
pain, play a major role in disease management.  The following discussion will focus on the 
advantages and disadvantages of current local therapies for canine OS. 
 
Surgery  
 Surgical resection of the primary tumor followed by either a platinum- or doxorubicin-
based chemotherapy protocol generally results in the longest median survival times [230-234].  
For appendicular OS, surgical options include amputation or limb-sparing procedures.  High 
amputation of the affected limb is the standard local treatment, and most dogs function well 
after this procedure, retaining good mobility and quality of life [214, 235].  An advantage of 
amputation is that it usually ensures complete local tumor removal. However, in cases where 
severe preexisting conditions exist, such as obesity, orthopedic or neurological disease, limb 
amputation may not be a viable option [214].  Additionally, this surgery may be undesirable to 
owners for cosmetic or psychological reasons.  In select cases, a limb-sparing surgery may be an 
alternative to amputation, in which the affected bone is resected and replaced by a normal 
bone allograft, metal endoprosthesis, or other less common methods [214, 236].  Overall, 
outcome  has been acceptable following limb salvage, with approximately 80% of dogs 
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experiencing good to excellent limb function [237].  A disadvantage of limb-sparing surgery is 
the relatively high rate of local complications including recurrent disease, construct failure, and 
post-operative infection [236].  In dogs, infections rates ranging from 40-60% have been 
reported, although quality-of-life and limb functionality were typically acceptable when 
infection was adequately controlled with systemic antibiotics [236-238].  Other drawbacks 
include the necessity for stringent case selection (i.e. distal radius, less than 50% bone 
involvement) to produce good results, and that access to this procedure is limited by surgical 
expertise, financial resources, and owner dedication [214]. 
 
Radiation Therapy  
 Radiation therapy (RT) for OS management may be utilized in the setting of palliative- or 
curative-intent therapy.  The goal of palliative radiation therapy (PTRT) is to decrease pain and 
lameness associated with OS, while inducing minimal to no radiation-induced adverse effects 
[239, 240].  Although the exact mechanism is unknown, alleviation of clinical signs is proposed 
to be the result of disruption of inflammatory cells, decreased progression of tumor-induced 
osteolysis, and reduction of tumor size [239, 241].  In dogs that are not good surgical candidates 
(i.e concurrent disease or advanced stage) or in which surgery is declined, PTRT is achieved with 
radiation protocols delivering multiple large fractions to the primary tumor.  Various reported 
protocols, delivering anywhere from 2-4 fractions and a total dose of 16-30 Gray (Gy) with or 
without concurrent chemotherapy, have resulted in similar short term outcomes with response 
rates and median onset to pain relief in the range of 74-93% and 11-21 days, respectively [242-
248].  Unfortunately, the duration of response to PTRT is limited, lasting a median 53-103 days, 
and survival tends to be restricted by patient comfort (approximately 2-3 months) [242-248].   
 Curative-intent radiation therapy for the management of canine OS has also been 
described in a number of settings including curative intent fractionated external beam protocol 
(CI-F), extracorporeal  intra-operative irradiation (IORT), stereotactic radiosurgery (SRS), and 
the gamma knife [249-252]. CI-F radiation therapy has been reported only twice with limited 
success, offering no substantial improvement in outcome over palliative protocols [251, 253].  
Limb-sparing with extra-corporeal IORT allows for a single 70 Gy fraction to be safely delivered 
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to the tumor during surgery while sparing adjacent normal and radiosensitive soft tissue 
structures [250].  This technique has been reported for distal radius, proximal humerus, and 
distal tibia [250, 254], and results in clinical improvement with good to excellent limb function 
in 77% of dogs [250].  When combined with chemotherapy, survival was comparable to other 
definitive strategies (MST- 298 days); however, post-operative complications were common 
(69-100%), including infection, fracture, and implant failure [250, 254].  SRS and the gamma 
knife are types of RT that utilize multiple, focused beams of radiation to deliver an entire dose 
in 1-3 treatments while minimizing damage to the surrounding tissues.  A major advantage of 
these techniques are their extreme accuracy of delivery and steep dose gradient, resulting in a 
possibly greater biological effect in a single dose, all while remaining well-tolerated [239, 249, 
252].  When combined with chemotherapy, overall survival times appear similar to standard of 
care therapies (MST 363 days), although a small number of dogs have been treated [249, 252].  
Major disadvantages of SRS and the gamma knife include the need for highly specialized 
equipment/ personnel and careful case selection, as dogs with metastatic disease, advanced 
osteolysis, and large tumor volumes (> 5 cm in diameter) are not good candidates [239].  
Additionally in theory, patients may be prone to bone fracture as radiation therapy is not 
selective for tumor cells and normal osteoblasts and stromal elements would also be affected. 
 Bone-seeking radioisotopes are another method of radiation delivery to the tumor.  The 
most commonly reported radioisotope used in canine and human OS is samarium-153-
lexidronam [255], which is targeted to areas of increased bone metabolism by the ligand 
lexidronam [255].  In canine OS patients, tumor doses equivalent to 20 Gy may be deposited 
using low to moderate doses, and the tumor to surrounding tissue dose ratio is favorable.  
While modest pain relief and some delay in tumor growth have been documented, treatment 
outcome is not predictable [256-258].  Additionally, cost and availability may limit its use. 
 
Chemotherapy 
 Chemotherapy agents that have demonstrated  efficacy in the treatment of OS include 
the platinum agents and doxorubicin [214].  While chemotherapy is primarily used in the 
management of canine OS for the purpose of delaying onset of metastasis, it may also be 
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employed in local therapy as a pretreatment to amputation or limb salvage.  In pediatric OS, 
neoadjuvant chemotherapy is used to reduce tumor volume in order to facilitate limb-sparing 
surgery [259] and also to assess in vivo treatment response by change in size and histologic 
evaluation.  As assessed by percent tumor necrosis (Huvos score), histologic response to 
neoadjuvant chemotherapy has been shown to be an independent prognostic factor in both OS 
and Ewing’s sarcoma [260-265].  In veterinary medicine, studies that evaluated dogs receiving 
intra-arterial (IA) cisplatin prior to limb spare surgery found that cisplatin IA with or without 
radiation therapy induced a significantly greater percent tumor necrosis when compared with 
dogs receiving no pretreatment, and that percent tumor necrosis was strongly predictive of 
local tumor control [266, 267].  An alternative method is isolated limb perfusion (ILP), which 
allows for delivery of high concentrations of chemotherapy locally, and is used in people with 
sarcomas as the sole treatment or to downstage local disease prior to limb sparing [214].  
Finally, a local polymer chemotherapy implantation can be used at the time of surgery and may 
delay onset of local recurrence [238, 268].  A clear disadvantage of chemotherapy used for local 
treatment is the potential for systemic off-target toxicities.  
 
Pharmacologic palliation 
 In addition to radiation therapy, palliation of bone pain may be achieved through the 
use of analgesics and bisphosphonates.  Aminobisphosphonates are drugs which both impede 
osteoclastic activity and induce osteoclast apoptosis, and therefore, are ideally suited for 
treating malignant bone pain and delaying progression of bone lesions [269, 270].  In canine 
appendicular OS, pamidronate and zoledronate have been evaluated as sole agents or in 
combination with radiation therapy [271-273].  In dogs receiving pamidronate alone, 28% of 
dogs had pain alleviation for greater than four months, lasting a median of 321 days [273].  In 
these dogs, significant increases in primary tumor bone mineral density were seen [273].  When 
combined with radiation and standardized analgesic therapy, adjuvant pamidronate did not 
clearly improve pain alleviation; however, a subset of dogs experienced decreased focal bone 
resorption in the local tumor environment [271].  On the whole, bisphosphonate drugs appear 
to be safe and may provide pain relief and/or delay onset of fracture in a subset of dogs [271-
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273].  More recently, concerns have arisen that pamidronate may be associated with a 
decreased survival time in canine OS patients; however, definitive conclusions are yet to be 
made [274]. 
 
2.8.2 Molecular and genetic abnormalities: evidence for aberrant apoptosis in canine OS 
 Recent experimental evidence suggests that aberrations in specific molecular pathways 
likely play a role in the pathogenesis of OS and that dogs and humans probably share common 
genomic imbalances [216, 275].  Many of these molecular changes result in dysfunction of 
upstream regulators of apoptosis, and one can begin to recognize how this may contribute to 
disruptions in the efficiency of the apoptotic pathway and to tumor development.  In humans, 
alterations affecting the tumor suppressor genes,  p53 and Rb (retinoblastoma),  are among the 
most frequently identified gene mutations in OS tumorigenesis [214, 216, 276, 277], the overall 
frequencies being 15-30% and 60%, respectively [278, 279].  Likewise, cytogenetic 
abnormalities have been demonstrated in dogs that are consistent with those previously 
reported in human OS, including gene dosage imbalances of known oncogenes and tumor 
suppressor genes [275].   
 
Tumor Suppressor Genes 
 As discussed previously, the P53 protein acts as a crucial regulator of cell replication and 
an initiator of apoptosis through transcriptional activation of specific genes (Figure 2.10). Thus, 
mutations in P53 can lead to unregulated replicative capacity and promote tumor development 
[280].  Similar to humans, P53 mutational inactivation has been described in both spontaneous 
OS and in vitro models in the dog [281-284].  The p53 gene is reported to be mutated and 
overexpressed, resulting in elevated levels of P53 protein in 84% of appendicular and 56% of 
axial cases of canine OS [285, 286].  In one study population, p53 mutations were identified in 
40% of OS from all skeletal sites [287].  Additionally, mutation status correlated with  
significantly shorter survival times, as well as with known poor prognostic indicators, such as 
elevated alkaline phosphatase concentration and tumor histological grade [287]. 
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PTEN (phosphatase and tensin homolog deleted on chromosome 10) is another 
important tumor suppressor gene that is mutated in a wide range of human malignancies [288].  
PTEN prevents tumorigenesis through multiple mechanisms, including antagonism of the 
PIK3/AKT survival pathway, maintenance of genome stability, and regulation of cell migration; 
but also plays a role in tumor invasion and angiogenesis [289-292] (Figure 2.11).  PTEN 
expression has been evaluated in canine OS cell lines, and four out of five expressed high levels 
of the phosphorylated form of AKT (an indirect indicator of aberrant PTEN expression) while 
three out of five were essentially devoid of PTEN protein [293].  Recently, deletion of the PTEN 
gene was identified as the most common copy number loss (41%) in a study of OS cases in the 
dog looking for breed associated genetic abnormalities [275].   
 
Oncogenes 
 In addition to alterations in the tumor suppressor genes, many proto-oncogenes have 
been implicated in OS, although the role of these in the pathogenesis of OS remains unclear.  
Notable examples of oncogenes demonstrated to be overexpressed in canine and/or human OS 
with varying frequencies include erbB2/HER-2 (epidermal growth factor receptor 2) [294-297], 
c-myc [298], c-met [299], c-sis/PDGF (platelet derived growth factor) [298, 300], and c-kit [301].  
Additionally, insulin like growth factor-1 (IGF-I) and IGF binding proteins (IGFBPs) have been 
shown to contribute to the malignant phenotype in canine and human OS [302].  IGFs are the 
most abundant growth factors in normal bone, and have significant effects on bone remodeling 
and the regulation of osteoblasts [303].  OS cells in culture have been shown to express IGF-I 
receptors, proliferate in response to IGF-I, and display an anti-apoptotic phenotype in vitro 
[216, 304, 305].  However, in a study of dogs receiving a long acting analogue of somatostatin 
(OncoLAR) in addition to carboplatin, no differences were observed in primary tumor necrosis, 
apoptosis, or survival over chemotherapy alone, despite suppression of serum IGF levels [306].   
 While the complete picture regarding the role of molecular and genetic alterations in OS 
tumor development is still being developed, it is clear that multiple complex pathways appear 
to be involved [307].  Many of these pathways, when disrupted, have the potential to confer 
tumor cells the ability to avoid programmed cell death, and thus evidence exists that 
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resensitizing OS to apoptosis is a reasonable therapeutic strategy.  This may be achieved by 
targeting the specific molecular alterations or circumventing deregulated apoptosis by 
reactivating downstream effectors of cell death. 
 
2.9 Novelty of PAC-1 as a potential local treatment for OS 
 PAC-1 as a local treatment for OS may have theoretical advantages over currently 
available treatment options.  For example, in cases where a patient is neither a good candidate 
for amputation nor limb-salvage surgery for reasons described previously, effective induction of 
apoptosis in malignant osteoblasts by PAC-1 could represent an alternative “curative-intent,” 
limb-sparing strategy.  Based on evidence presented earlier, PAC-1 has several probable 
advantages.  First, in contrast to targeted radiotherapies, such as stereotactic radiation and 
radioisotopes, evidence suggests that PAC-1 is selective for cancer cells [208].  Sparing of 
normal osteoblasts and supportive bone stromal cells would have the obvious benefit of 
preserving maximum bone strength, thereby minimizing the incidence of local complications 
such as pathologic fracture.  Additionally, delivery of PAC-1 to dogs with OS is not likely to be 
limited by tumor location or stage or the need for specialized equipment, facilities, or expertise.  
Because of this, PAC-1 may be a good local treatment option for dogs regardless of confounding 
patient and owner limitations.  A third theoretical advantage is that PAC-1 may be chemically 
manipulated to specifically target bone, thus limiting off-target toxicities and increasing the 
concentration and efficacy of drug within the OS tumor microenvironment. 
 
2.9.1 Bone specific drug delivery: a potential strategy for prolonging bone tumor exposure 
to PAC-1 
 Bone is a unique tissue in that it is mainly composed of hydroxyapatite.  In fact, two-
thirds of the mineral mass in our bodies is estimated to be present in bone tissue [308, 309].  
Therefore, molecules that display a preferential affinity for hydroxyapatite have the potential to 
seek and concentrate in bone tissue, providing a distinctive opportunity for bone-targeted 
therapies [309].  In reality, there are very few therapeutics that exhibit a strong natural affinity 
for hydroxyapatite.  Thus, current approaches to designing bone-specific therapies have relied 
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on engineering a therapeutic agent with a bone seeking molecule—the former delivers the 
desired effect while the latter achieves the intended localization [309].  While multiple 
strategies have been investigated, approaches involving bisphosphonate conjugation appear to 
be the most promising and will be the primary focus here. 
 Bisphosphonates are a class of synthetic compounds that are structurally similar to 
pyrophosphate, an endogenous regulator of calcium homeostasis [310].  Because a portion of 
their chemical structure (the P-C-P bond) has a high affinity for calcium crystals, 
bisphosphonates are selectively trapped in calcified tissues, thereby inherently targeting bone 
tissue [308, 311].  Bisphosphonate conjugation via chemical linkage is an ideal technique for 
bone-specific drug delivery for the following reasons: 1) preferential binding to bones that have 
high-turnover rates suggests selectivity for areas of active bone remodeling (i.e malignant 
osteolysis), 2) resistance to chemical and enzymatic hydrolysis imparts a long half-life and 
sustained release, and 3) acidic and water-soluble properties limit distribution to soft tissues, 
except for the kidney where excretion occurs [308, 310, 312, 313].  A major pharmacokinetic 
drawback to bisphosphonate conjugates is the propensity for formation of colloids or 
precipitates, which may lead to changes in pharmacokinetic properties resulting in possible soft 
tissue disposition and damage [308, 314]. Consequently, it is important that dose, mode of 
administration, and type of linkage be optimized.  Another important consideration when 
designing bisphosphonate conjugates is the lipophilicity of the conjugate compound, as work in 
rats suggests that increased lipophilicity decreases the fractional dose of the bisphosphonate 
compound delivered to the skeleton after intravenous injection [315, 316].  Notably, 
development of nanoparticle technology has provided a cutting-edge alternative method of  
encompassing and “coating” a desired therapeutic agent with a bisphosphonate [317], and this 
may circumvent some of the aforementioned challenges in the future. 
 Bone-specific drug delivery systems using bisphosphonate conjugates in preclinical or 
clinical studies include estradiol [318-320], prostaglandin E2 [321], fluoroquinolones [322], 
cisplatin [323], melphalan [324], methotrexate [325], taxanes [326] and others [327, 328].  One 
interesting application aggressively investigated in clinical trials for palliation of bone 
metastases, is bisphosphonate coupled radiopharmaceuticals [329-334].  153Sm-EDTMP is a 
27 
 
bone-seeking tetraphosphonate, which has been approved by the Food and Drug 
Administration for the treatment of painful osseous metastases in people [335].  New 
bisphosphonate conjugates are currently under investigation, for example 188Re(CO)3-
dipicolylamine-alendronate, which has been shown to accumulate in areas of high metabolic 
bone activity while having low soft-tissue uptake [332].  The proposed conjugation of PAC-1 to a 
bisphosphonate is a rational strategy for delivering high doses of PAC-1 to bone in order to 
direct apoptosis within the OS microenvironment.  
 
2.10 Conclusion 
Resistance to apoptosis is one of the hallmarks of cancer development, and thus, 
treatments aimed at inducing apoptosis have recently been recognized as powerful anticancer 
tools.  Because caspases are at the heart of the apoptotic process and caspase-3 is a 
requirement for the cleavage events that lead to cellular death, therapies directed at activating 
executioner caspase proenzymes may be capable of circumventing upstream disruptions and 
provoking apoptosis within tumor cell populations.  PAC-1 is the first identified procaspase 
activating compound and has demonstrated promising proapoptotic and anticancer effects in 
vitro and in vivo.  Additionally, preliminary pharmacokinetic data in dogs suggests that 
achievement and maintenance of a therapeutically relevant dose of PAC-1 is feasible via 
intravenous CRI [211].  Canine OS is a common bone cancer of dogs that is biologically similar to 
pediatric OS.  Molecular and genetic evidence suggests that disruption in upstream regulators 
of apoptosis may contribute to the pathogenesis of canine and human OS.  Therefore, a 
molecule directed at induction of apoptosis, such as PAC-1, may be a viable local treatment 
strategy.  Methods for prolonging tumor exposure to effective drug concentrations include 
constant rate infusion and bone specific drug delivery. Bone specific delivery of PAC-1 via 
conjugation with a bisphosphonate would be expected to produce greater local tumor 
concentration and efficacy in addition to less off-target toxicity, and may provide advantages 
over current local treatment strategies.  Additionally, there may be a role for PAC-1 as a 
combination therapy as low doses could theoretically sensitize tumor cells to apoptotic cell 
death by other anticancer drugs such as chemotherapy. 
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From a broader prospective, bisphosphonate linked PAC-1 could have a more global 
application in human cancer as well, particularly with regards to the treatment of malignant 
osteolysis and pain caused by bone metastases. It is estimated that more than 350,000 people 
in the United States die with bone metastasis each year and the number of affected people 
increases when we consider those currently living with the condition, as many patients live 
greater than 1 year [336].  Breast, prostate, lung, renal, and thyroid carcinoma are most likely 
cancers to participate in osseous metastasis, making up over 90% of the metastatic lesions seen 
in people [337]. Interestingly, evidence presented previously shows that certain breast, lung, 
and kidney cancers also have elevated concentrations of procaspase-3, and thus, should be 
susceptible to the anticancer activity of PAC-1.  In conclusion, bone specific delivery of PAC-1 is 
a promising therapy, either used alone or as an adjunct to traditional treatments, for primary 
bone tumors and osseous metastases in people and dogs, although its safety and efficacy are 
not known at this time. 
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2.11 Figures 
 
 
FIGURE 2.1:  Final stage of Apoptosis.  Note the formation of apoptotic bodies, which are then 
recognized and consumed by neighboring macrophages. (http://ghr.nlm.nih.gov2010) 
 
 
FIGURE 2.2:  A. Caspase organization. A prodomain precedes the catalytic domain, composed of two 
covalently linked subunits. Sites for (auto)proteolysis at Asp residues are indicated. B. Activation 
mechanisms. Initiators are monomers that activate by prodomain-mediated dimerization. Executioners 
are dimers that activate by cleavage of intersubunit linkers. Following activation, additional proteolytic 
events mature the caspases to more stable forms, prone to regulation [29]. 
(http://www.jbc.org/content/284/33/21777/F1.expansion.html) 
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FIGURE 2.3: Schematic diagram of the structure of mammalian caspases. Three major groups of 
caspases are presented based on a common classification scheme. Group I: inflammatory caspases; 
group II: apoptosis effector caspases; group III: apoptosis initiator caspases. Note the CARD, the DED, 
and the large (p20) and small (p10) catalytic subunits [30]. 
(http://www.biochemj.org/bj/384/0201/bj3840201f01.htm) 
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FIGURE 2.4: Binding of TRAIL to TRAIL receptor (TRAILR/DR) or Fas-L to Fas results in receptor 
trimerization and recruitment of FAS-associated protein with death domain (FADD) and caspase-8 to 
form the death-inducing signaling complex (DISC). Upon DISC formation, initiator caspase-8 is cleaved 
and activated.  In turn caspase-8 can cleave and activate caspases-3 and BID. Active BID (tBID) binds to 
pro-apoptotic BAX and BAK, resulting in mitochondrial membrane permeabilization and release of 
cytochrome c and DIABLO (cross-talk). Caspase-3 goes on to cleave intracellular targets resulting in 
apoptosis and can also activate caspase-8, thereby amplifying the apoptotic signal [53].  Adapted from 
(http://www.nature.com/nrc/journal/v8/n10/fig_tab/nrc2465_F1.html) 
 
 
FIGURE 2.5:  Death Effector Domain (DED) containing c-FLIPs are compared to FADD and caspase-8/10. 
Structural homology domains are indicated.  Note the pseudo-caspase domain of c-FLIPL [83]. 
Fas-L 
Fas 
c-FLIP 
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FIGURE 2.6: Mitochondrial Pathway. The core of the pathway is the process of mitochondrial outer 
membrane permeabilization (MOMP), mediated by the proapoptotic Bcl-2 family members, Bax and 
Bak, and inhibited by the anti-apoptotic Bcl-2 family proteins. The BH3-only proteins regulate MOMP by 
promoting Bax and Bak and by antagonizing anti-apoptotic Bcl-2 proteins.  As a result of MOMP, 
proteins from the intermembrane space gain access to the cytosol. Cytochrome c triggers activation of 
APAF-1, leading to apoptosome formation and activation of caspase-9. Caspase-9, in turn, cleaves and 
activates executioner caspases 3 and 7 to orchestrate apoptosis. IAPs inhibit caspase activation; this 
inhibition can be reversed by IAP antagonists (e.g. Smac and Omi) also released from the mitochondria 
upon MOMP [89]. (http://www.sciencemag.org/cgi/content/full/310/5745/66/FIG1) 
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FIGURE 2.7: Apoptosome formation. Cytochrome c binding induces an ATP dependent conformational 
change in Apaf-1 that exposes its CARD domain.  The CARD domains of seven Apaf-1 molecules interact 
to form a wheel-like heptameric structure where procaspase-9 will be recruited by CARD/CARD 
interactions to the hub of the apoptosome (Adapted from Colin et al. 2009) [338]. 
 
 
FIGURE 2.8: XIAP interacts with caspase-3 and -9. XIAP is depicted with BIR1 at the N- terminus, and the 
RING domain at the C- terminus. The caspases are shown in their dimeric structure, with large subunits 
in grey, small subunits in blue, and active-site substrate pockets (S-designation) as yellow dots. 
Inhibition of caspase-3 (and caspase-7) is achieved mainly by docking of the 'hook' and 'sinker' regions 
between the BIR1 and BIR2 domain.  The BIR3 domain is used to inhibit caspase-9 [146]. 
(http://www.nature.com/nrm/journal/v3/n6/fig_tab/nrm830_F3.html)  
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FIGURE 2.9: Mechanism of Action of PAC-1. PAC-1 activates procaspase-3 and induces apoptotic cell 
death through the chelation of inhibitory zinc ions (scs.uiuc.edu/~phgroup/research1.html). 
 
 
FIGURE 2.10: P53 expression leads to growth inhibition and apoptosis.  Following DNA damage, p53 
expression induces the cyclin kinase inhibitor p21, resulting in cell cycle arrest, and bax, which induces 
apoptosis.  The p53 pathway is linked to Rb through p21, which inhibits cyclin dependent kinase 4 and 
promotes cellular proliferation through inactivation of Rb [152]. 
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FIGURE 2.11: PTEN negatively regulates signal transduction and cancer development.  A. PTEN 
negatively regulates PI3K activity in the AKT signaling pathway, preventing excessive cell proliferation. B. 
In the absence of PTEN, increased activity of AKT leads to activation of mTOR and a subsequent increase 
in cell division. Checkpoints that would usually halt division of aberrant cells are overridden, leading to 
an accumulation of mutations and possibly malignant transformation (Nature 2006) [339]. 
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CHAPTER 3 
INVESTIGATING A PROCASPASE ACTIVATOR, PAC-1, IN CANINE, MURINE, AND HUMAN 
OSTEOSARCOMA CELL LINES 
 
3.1 Introduction 
Apoptosis is a specialized, active form of cell death that is important in both health and 
disease.  It is responsible for maintaining regulated development and tissue homeostasis and 
participates in the elimination of aged, damaged, or displaced cells [1-4].  Apoptosis is also an 
inherent tumor suppressive mechanism, and the ability of cancer cells to evade death is widely 
acknowledged as one of the hallmarks of cancer development [3, 4, 7, 8].  In tumor cell 
populations, disruptions in apoptosis commonly occur through modulation of key players in the 
apoptotic cascade—particularly inactivation or downregulation of pro-apoptotic proteins and 
overactivation or upregulation of anti-apoptotic proteins [167-169].   
Classically, there are two main pathways which trigger apoptosis, both of which revolve 
around the activation of a key family of cysteine proteases, called caspases, which cleave 
cellular substrates after C-terminal aspartate residues [3-5, 32, 45].  The extrinsic pathway is 
initiated by ligation of death receptors, which leads to engagement of adaptor proteins and 
formation of the death inducing signaling complex (DISC) [39, 46].  The result is recruitment and 
activation of the initiator caspase-8 [68].  The intrinsic pathway, also known as the 
mitochondrial pathway, is activated by cellular stress and mediated by pro-apoptotic Bcl-2 
family members’ induction of mitochondrial outer membrane permeabilization (MOMP) [52, 
57, 89, 90].  Following MOMP, cytochrome c release into the cytoplasm leads to assembly of 
the apoptosome, which in turn recruits and activates the initiator caspase-9 [91, 125, 126]. 
Ultimately, both pathways converge at the cleavage of procaspase-3 to caspase-3, the key 
“executioner” caspase that cleaves hundreds of cellular substrates, leading to cell death [69, 
127-129]. 
Caspases exist in the cell as zymogens, where the proteolytic activity of inactive 
executioners is restrained by a linker region.  During activation, cleavage at specific Asp 
residues divides the amino acid chain into active p12 and p17 catalytic subunits [29, 31, 32].  
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Cancer cells often have upstream defects in apoptotic machinery that prevent efficient 
procaspase activation [3, 4, 7, 8, 30, 52].  Because the activation of caspase-3 is a committed 
and shared pathway for apoptosis, compounds that directly activate procaspase-3 have the 
potential to bypass these defects and restore effective apoptosis.  Additionally, procaspase-3 
levels are elevated in some cancers suggesting theoretical selectivity for tumor over normal 
cells [198-204, 208].  This, along with the pivotal and downstream location of procaspase-3 in 
the apoptotic cascade, makes the direct activation of procaspase-3 with a small molecule an 
attractive, novel anti-cancer therapy [208, 340]. 
The discovery of Procaspase-Activating Compound 1 (PAC-1), an ortho-hydroxy N-acyl 
hydrazone, was reported in 2006 by Putt et al. [208, 210].  PAC-1 enhances the enzymatic 
activity of procaspase-3 in vitro by chelation of inhibitory zinc ions from the “labile zinc pool” 
allowing auto-maturation of procaspase-3 to its active form [208-210].  It also has been 
demonstrated to induce apoptosis in cancer cells and shown efficacy in multiple murine tumor 
models [208].  PAC-1 has been safely administered to mice and research dogs at doses that give 
serum concentrations of 10 μM for 48 hours; however, neuronal hyperexcitation is dose-
limiting and becomes a significant concern at higher serum concentrations [211, 341, 342].  
Because of this undesirable side effect, administration of native PAC-1 as a sole agent is 
problematic, and targeting strategies which generate high concentrations of PAC-1 within the 
immediate tumor microenvironment or PAC-1 derivatives with attenuated neuronal 
hyperexcitation characteristics are likely to be more viable therapeutic options.  Other potential 
strategies include increased duration of exposure to lower, tolerable doses of PAC-1 and use of 
procaspase activating compounds as a low dose, sensitizing agent for other chemotherapeutics.  
Increasing duration of exposure may be achieved through constant rate infusion or 
hydroxyapatite binding (bone delivery) strategies.  Recently, a sulfonamide containing 
derivative, S-PAC-1, was investigated in mice and in pet dogs with spontaneously occurring 
lymphoma, and found to be well tolerated and effective at reducing or stabilizing tumor growth 
in 4 out of 6 patients without induction of neurotoxicity [341].  These findings support the 
investigation of targeted procaspase-3 activating strategies, which may provide greater 
therapeutic benefits with less off-target toxicity.   
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Osteosarcoma (OS) is the most common primary bone tumor of dogs, accounting for 
approximately 85% of malignancies arising in the skeleton [212-215].  Malignant osteolysis is 
the major presenting complaint and cause of patient morbidity [214], and surgical removal of 
the tumor is not always a viable option due to patient and owner considerations [214].  
Effective palliative strategies for bone pain are limited.  For example, stereotactic radiosurgery 
(SRS) is highly effective but costly and requires specialized equipment [239, 249, 252].  
Response to bone seeking radioisotopes is unpredictable and its use limited by availability [257, 
258, 343], and palliative radiation and bisphosphonates, while widely available, are constrained 
by the relatively short durability of clinical responses [242-248, 273].  Thus, novel localized 
therapies are clinically justified for canine OS, making this a reasonable model to investigate a 
targeted procaspase-3 activating drug.   
The primary goal of the present study was to investigate PAC-1’s pro-apoptotic effects in 
canine, murine, and human OS cell lines.  Our study hypothesis was that biologically tolerable 
concentrations of PAC-1 could induce apoptosis in OS cells in a manner consistent with the 
known mechanism of action of PAC-1.   
 
3.2 Materials and methods 
3.2.1   Cell lines 
Four canine OS cell lines (HMPOS, Abrams, Cos31 and D17), two murine OS cell lines 
(K7M2 and DLM8), and two human OS cell lines (MG63 and 143B) were used for 
experimentations.   The MCF7, a human breast cancer cell line known to be negative for the 
expression procapspase-3, was used as a negative control.  The cells were maintained in 
Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% fetal bovine serum 
(FBS), penicillin, streptomycin and plasmocin (Invitrogen, Carlsbad, CA).    All adherent cell 
cultures were grown in cell culture plates (Corning, Inc., Corning, NY) and were maintained at 
37oC in 5% CO2 and passaged twice weekly or more frequently if needed to maintain cell 
viability.  When needed for experimentation, cells were harvested and counted with a 
hemacytometer.  A trypan blue dye exclusion test was performed on each respective cell line 
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prior to experimentation to ensure high viability (> 90%)  (Hazleton Research Products, Denver, 
PA). 
 
3.2.2 Reagents and antibodies 
A monoclonal rabbit anti-caspase-3 (8G10) antibody (Cell Signaling Technology, Danvers, 
MA), which recognizes both intact procaspase-3 and large fragment (p19/17) of caspase-3, was 
used as a primary antibody for western blotting.  As a secondary antibody, a donkey anti-rabbit 
IgG:HRP antibody (GE Healthcare Amersham Piscataway, NJ) was used in conjunction with a 
commercially-available Enhanced Chemiluminescent detection kit (Pierce, Rockford, IL).   PAC-1 
was synthesized and generously provided by the Hergenrother Laboratory (University of Illinois, 
Department of Chemistry).  For in vitro experimentations, PAC-1 was dissolved in 99.5% DMSO 
(Sigma, Saint Louis, MO) at a 10 mM stock concentration and kept frozen at -20oC until needed.   
 
3.2.3 In vitro analysis of procaspase-3 expression 
Western blot was performed for detection of the target, procaspase-3, in canine, 
murine, and human OS cell lines.   After incubation, OS cells were harvested from cell culture at 
60-70% confluence.  Media was discarded; cells were washed once in neutral phosphate 
buffered saline (PBS) and incubated with 1 ml 0.25% Trypsin (Thermo Scientific, Logan, UT) for 5 
minutes.  Fresh medium was added and cell suspensions were collected in conical tubes, 
centrifuged, and washed once with neutral PBS.  For protein extraction, cells were re-pelleted, 
incubated with an appropriate quantity of Mammalian Protein Extraction Reagent (M-PER, 
Thermo Scientific, Rockford, IL) and protease inhibitor cocktail (Thermo Scientific, Rockford, IL) 
(100:1) and shaken at room temperature for 15 minutes.  Following incubation, cell lysates 
were centrifuged and the supernatant was collected.  Protein quantification was determined 
using the Pierce BCA Protein Assay kit (Thermo Scientific, Rockford, IL) according to the 
manufacturer’s instructions.   
For analysis by SDS-PAGE electrophoresis, 50 µg of protein from each sample was boiled 
in Laemmli’s sample buffer with 2-mercaptoethanol reduction at 95˚C for 5 minutes.  The 
samples were then briefly placed on ice and loaded in 4–15% Mini-PROTEAN® TGX™ Precast 
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polyacrylamide gels (BioRad Hercules, CA ) in SDS-PAGE electrophoresis buffer.  Precision Plus 
Protein™ WesternC™ (BioRad Hercules, CA ) was used for the protein standard, and gels were 
run at 80V until completion.  Proteins were then transferred to the Millipore PVC membrane 
using the Mini Trans-Blot (BioRad Hercules, CA ) at 53V for 45 minutes.  For detection of 
procaspase-3 protein, the membrane was blocked in 5% milk (in TBS-T) for 1 hour, washed 
three times with TBS-T, and then incubated with the primary antibody at a 1:500 dilution at 
room temperature for 1 hour.  The membrane was then washed and incubated with secondary 
antibody at a 1:1000 dilution for 1 hour and digitally developed using a BIO-RAD ChemiDoc 
XRS+ System. 
 
3.2.4 In vitro PAC-1 target modulation studies 
Cells were initially cultured in cell culture plates (Corning, Inc., Corning, NY) for target 
modulation assays.  When cells reached 50-60% confluence, the media was discarded and the 
cells were washed once with neutral PBS.  Fresh medium containing varying concentrations of 
PAC-1 was added to cell culture plates  at 0, 3, or 10 µM of PAC-1 for either 12, 24, or 48 hours 
of exposure at 37˚C in 5% CO2.  For analysis of target modulation, protein was collected and 
western blot was performed as indicated previously to qualitatively determine changes in full 
length procaspase-3 and cleaved caspase-3 expressions. 
 
3.2.5 In vitro caspase-3 activation  
A caspase-3 activation study was performed exposing the HMPOS cell line to vehicle 
control or 10 μM of PAC-1 for 24 and 48 hours at 37oC in 5% CO2.  In experiments, cells that 
were not exposed to PAC-1, but were exposed to DMSO, served as a vehicle control population.  
200,000 cells per time point were analyzed and all tests were performed in triplicate.  The 
evaluation of active caspase-3 was analyzed using a caspase-3 colorimetric assay (R & D 
Systems, Minneapolis, Minnesota).  The assay was performed according to manufacturer’s 
instructions.  Briefly, once the cells were exposed to the PAC-1 and centrifuged, the media was 
discarded and the cell pellet was lysed with a provided lysis buffer.  The cell lysate was 
incubated on ice for 10 minutes, centrifuged, and the supernatant preserved.  The supernatant 
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was aliquoted to a 96 well microplate (Fisher Scientific, Pittsburgh, Pennsylvania) with 50 µL in 
each well, with 5 µL caspase-3 colorimetric substrate (DEVD-pNA) and a reaction buffer added.  
The plate was incubated at 37oC for 2 hours.  The plate was read on a Bio-Tek EL-800 microplate 
reader using a 405 nm wavelength.  All values were expressed as a fold increase over vehicle-
treated control cells.  
 
3.2.6 In vitro PAC-1 cytotoxicity studies 
For cytotoxicity assays, HMPOS cells were also initially cultured in cell culture plates.  
After incubation, the cells were harvested and seeded into 12-well plates at 50,000-75,000 
cells/well, and allowed to adhere overnight.  Fresh medium containing varying concentrations 
of PAC-1 was added to respective wells at 0, 1, 3, and 10 µM of PAC-1 for 48 hours of exposure 
at 37oC in 5% CO2.  All conditions were performed in triplicate.  For analysis of cytotoxicity, an 
Annexin V-FITC PI apoptosis detection kit (BD Pharmingen, San Diego, California) was used 
according to the manufacturer’s directions.  Briefly, once the cells had incubated under their 
respective conditions, the cells were harvested and washed twice in previously reconstituted 
cold high calcium binding buffer (Annexin Binding Buffer, BD Pharmigen, San Diego, California).  
The analysis was performed in triplicate with 100,000 cells per flow tube.  Next, 5 µL of FITC, 5 
µL PI, and 100 µL of high calcium binding buffer were added to each flow tube and gently 
vortexed.  The cells were then allowed to incubate at 4oC in the dark for 15 minutes.  400 µL of 
cold high calcium binding buffer was added to each flow tube and the cells were analyzed via a 
Coulter flow cytometry within one hour. 
   
3.2.7 Statistical analysis 
Differences in caspase-3 enzymatic activity in HMPOS cells treated with vehicle or PAC-1 
at 10 µM for either 24 or 48 hours were compared using the Student’s t-test.   Analyses were 
compared based upon treatment agent (vehicle or PAC-1) for the 2 different incubation 
durations (24 and 4 hours).  The effect of PAC-1 concentration (1-10 µM) for 48 hours of 
incubation on HMPOS cell viability was compared with a 1-way ANOVA test.  If groups were 
identified as being different, a Dunnett’s post hoc test was performed to identify which 
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concentration of PAC-1 (1-10 µM) differed from the vehicle treated group. Significance was 
defined as p < 0.05. 
 
3.3  Results 
3.3.1  Procaspase-3 is expressed in osteosarcoma cell lines 
Immunoblotting analysis showed that the canine (Abrams, HMPOS, Cos31, D17), murine 
(K7M2, DLM8) and human (143B, MG63) OS cell lines all express procaspase-3, indicating that 
the commercial antibody for procaspase-3 is species cross-reactive and that there is 
homologous protein conservation of the procaspase-3 target among the species in question.  
Expression of the 35 kDa protein was detected in all cell lines, but not in the negative control 
MCF7 (Figure 3.1).  Notably, in the canine cell lines, procaspase-3 appeared as a double band 
rather than a single band, as is identified for human and murine procaspase-3. 
 
3.3.2 Incubation with PAC-1 results in modulation of the target procaspase-3 to cleaved 
caspase-3 
The concentration of PAC-1 assessed in vitro was chosen based on unpublished 
maximum-tolerated dose data from canine studies performed in the Cancer Care Clinic through 
the conductance of a Phase I study in dogs with multicentric lymphoma.  From these in vivo 
studies, serum concentrations of PAC-1 maintained below 15 µM for 24-48 hours were 
biologically tolerable.  Thus, 12, 24 or 48 hour incubations were performed with 3 or 10 µM 
concentration of PAC-1, and target modulation assessed in 3 representative species cell lines 
(human-143B, murine-K7M2, and canine-HMPOS).  Subsequently, western blotting was used to 
detect the expression of procaspase-3 and its active, cleaved counterpart, caspase-3, following 
PAC-1 exposure.  Incubations with both 3 and 10 µM concentrations of PAC-1 resulted in 
modulation of the target procaspase-3 in all cell lines and automaturation to its active form 
(Figure 3.2).  This was supported by decreasing procaspase-3 band intensity with increasing 
length of incubation and concentration of PAC-1.  Simultaneously, increasing intensity of the 
fully processed 17 kDa fragment of cleaved caspase-3 was also seen in a dose and time 
dependent manner (Figure 2.2).  These changes were not noted in OS cell lines incubated with 
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media alone or DMSO vehicle.  Of note, the detection of the 17 kDa fragment of cleaved 
caspase-3 was less intense at 48 hours in comparison with 24 hours in both murine and human 
OS cell lines exposed to 10 µM of PAC-1. 
 
3.3.3 Incubation with PAC-1 increases caspase-3 activity in HMPOS cells 
To confirm that the modulation of procaspase-3 to caspase-3 observed by western blot 
analysis produced proteolytically active caspase-3 in the HMPOS cell line, an enzymatic 
methodology to detect changes in cytosolic caspase-3 activity was used.  HMPOS cells were 
incubated with either DMSO vehicle or PAC-1 at 10 µM for 24 and 48 hours, and cytosolic 
fractions collected and mixed with a colorimetric caspase-3 substrate.  Following 24 hours of 
incubation, there was no significant difference in percent fold increase of cytosolic caspase-3 
activity between vehicle control and PAC-1 treated HMPOS cells (100 ± 9.5% and 93.0 ± 12.2%, 
respectively; p=0.59).  However, upon 48 hours of exposure, PAC-1 at 10 µM resulted in a 
significant percent fold increase in cytosolic caspase-3 activity (~50%) compared to vehicle 
control (153.4 ± 6.9% versus 100 ± 0.4%, respectively; p=0.008) (Figure 3.3).  The demonstration 
of augmented caspase-3 activity after 48 hours of exposure to PAC-1 at 10 µM in comparison 
with vehicle control treated cells is complementary to the findings demonstrated by western 
blot analysis showing the conversion of procaspase-3 to the 19 kDa subunit of caspase-3 after 
48 hours of PAC-1 exposure (Figure 3.2). 
  
3.3.4 Incubation with PAC-1 induces apoptosis in the canine HMPOS cell line 
Given the observed processing of procaspase-3 to caspase-3 by western blot analysis, in 
conjunction with the identification of increased caspase-3 enzymatic activity induced by PAC-1, 
the biologic consequences of procaspase-3 activation by PAC-1 was investigated in the canine 
HMPOS cell line.  Specifically, it was to be determined if procaspase-3 activation by PAC-1 
demonstrated by western blot and enzymatic activity studies would result in cell death via the 
induction of apoptosis.  Experimentally, HMPOS cells were exposed to varying low 
concentrations of PAC-1 ranging from 1-10 µM for 48 hours, and the percentage of cells 
categorized as viable and early apoptotic were quantified.  Viable cells were defined as being 
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negative for both Annexin V FITC and propidium iodide staining, while early apoptotic cells 
were defined as being positive for Annexin V FITC staining, but negative for propidium iodide 
staining.  Viability of HMPOS cells remained above 92% for cells incubated with media only, 
vehicle, and PAC-1 at 1 and 3 µM, with no statistical differences identified (Figures 3.4 and 3.5).  
However, when HMPOS cells were exposed to PAC-1 at 10 µM for 48 hours, a dramatic 
reduction in cell viability percentage was observed with an average viability of 9.9 ± 1.0% 
(p<0.001 when compared with media or vehicle control treated cells). 
The loss of cell viability was further characterized as being most consistent with the 
early stages of apoptosis based upon the identification of HMPOS cells which stained positively 
for Annexin V FITC, but negative for propidium iodide (Figures 3.4 and 3.6).  Exposure to PAC-1 
at 10 µM for 48 hours exerted a significant and potent pro-apoptotic effect on HMPOS cells, 
with 87.7 ± 1.6% cells staining positive for Annexin V FITC only, in comparison with basal 
apoptosis percentage identified in HMPOS cells incubated with media alone, 1.3 ± 1.1%; p<0.01.  
In addition, a significant increase in apoptotic cells was also observed with PAC-1 at 3 µM for 48 
hours, with 3.7 ± 0.6% of HMPOS cells labeling with only Annexin V FITC (Figure 3.6). 
   
3.4 Discussion 
 This is the first report to specifically investigate procaspase-3 expression in OS cells and 
the action of PAC-1, a procaspase activating compound, on these cells.  The present study 
confirms the expression of procaspase-3 in canine, murine, and human OS cells and 
demonstrates that PAC-1 is capable of converting procaspase-3 to caspase-3 and subsequently 
inducing apoptosis in canine OS cell lines.  This occurs as a result of increased caspase-3 activity 
as expected based on the reported mechanism of action of PAC-1. 
Prior to investigating the use of PAC-1 as a viable anticancer strategy against canine OS, 
it was important to first demonstrate the presence of the target procaspase-3 in OS cell lines.  
All OS cell lines evaluated (canine, murine, and human) expressed the target procaspase-3, 
indicating homologous protein conservation among the species investigated.  To the author’s 
knowledge, no studies have specifically examined the expression of procaspase-3 in OS cells.  
However, our results support the findings of other investigations that have suggested caspase-3 
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mediated induction of apoptosis in OS cell lines following exposure to a pro-apoptotic 
compound [344, 345].   
Notably, the present findings indicate that the relative cellular quantities of procaspase-
3 as subjectively determined by western blot analysis (band darkness) is greater in human and 
murine cell lines when compared to canine cell lines.  It is possible that this apparent difference 
cellular target is due to suboptimal antibody cross-reactivity against canine procaspase-3.  
Alternatively, procaspase-3 might truly be reduced in canine OS cell lines in comparison with 
murine and human cell line counterparts.  If the latter is true, this could suggest that 
procaspase-3 activating strategies might be more effective in the treatment of OS developing in 
humans and mice, than in dogs.  Furthermore, our studies consistently identified the presence 
of a double band for procaspase-3 in all canine OS cell lines.  Plausible reasons for the observed 
protein doublet include a variance in antibody specificity that allows cross-reactivity with 
another protein of a similar molecular weight or the existence of an alternate procaspase-3 
splice variant in dogs. 
Following demonstration of the target, we investigated the ability of PAC-1 to induce 
the conversion of procaspase-3 to its active form, cleaved caspase-3.  Our findings indicate that 
exposure to low, biologically relevant concentrations of PAC-1 (3 and 10 µM) promote the 
automaturation of procaspase-3 to caspase-3 in all cell lines investigated (HMPOS, K7M2, 
143B).  Western blot analysis supported both a time and dose dependent effect of PAC-1 on 
target modulation, as demonstrated by greater decreases in procaspase-3 with concurrent 
increases in cleaved caspase-3 following longer durations of exposure and higher 
concentrations of PAC-1.  Importantly, the findings from this study suggest that for lower 
concentrations of PAC-1 to exert biologic effects, a concurrent increase in exposure time is 
necessary to activate procaspase-3.  The relationship between exposure duration and 
concentration, in context with PAC-1’s neuroexcitatory potential, emphasizes the requirement 
for delivery strategies that will result in prolonged exposure durations with low concentrations 
of PAC-1 within the bone tumor microenvironment for the safe and effective management of 
primary bone OS.   
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Although a time-dependent effect of PAC-1 on procaspase-3 modulation was identified 
between 12 and 24 hours, an exception to this time-dependent trend was observed following 
48 hour incubation with PAC-1, in which lesser amounts of both the partially (p19) and fully 
processed (p17) large subunit of cleaved caspase-3 were observed.   Although these findings 
appeared counter-intuitive, several potential explanations exist for this observation.  The first is 
ubiquitin-mediated proteasome degradation of caspase-3 following PAC-1 activation.  Inhibitor 
of apoptosis proteins (IAPs) can mediate this degradation by directly binding caspases and 
acting as ubiquitin E3 ligases, and evidence suggests that this might be enhanced in cancer cells, 
thus contributing to apoptotic resistance [346, 347].  An alternative explanation for this 
observation is the temporal depletion of procaspase-3 as a substrate for conversion to caspase-
3, which could be due to either decreased viability of the cells at latter time points (48 hours) or 
procaspase-3 substrate exhaustion. 
Another interesting finding of the present study was that the canine HMPOS cell line 
appeared more resistant to PAC-1 activation in comparison with murine (K7M2) and human 
(143B) OS cells.  This supposition is based on the predominance of the 19 kDa fragment rather 
than the 17 kDa fragment of caspase-3 identified by western blot analysis in HMPOS cells, but 
not in either K7M2 or 143B cells.  The reduced capacity of PAC-1 to process procaspase-3 to the 
fully activated 17 kDa caspase-3 fragment in HMPOS cells could be explained by greater 
inherent expressions of counter-regulatory IAP in comparison with the murine K7M2 and 
human 143B OS cell lines.    
Because western blot only detects the presence of protein and not its enzymatic 
functionality, it was necessary to confirm that the modulation of procaspase-3 to caspase-3 
observed by western blot coincided with production of proteolytically active caspase-3.  We 
found that 48 hours of exposure to PAC-1 at 10 µM in HMPOS cells resulted in a significant 
increase in cytosolic caspase-3 activity (~50%) compared to vehicle control.  In contrast, there 
was no significant difference in cytosolic caspase-3 activity after a 24 hour incubation of 10 µM 
PAC-1 in HMPOS cells.  Our findings suggest that the induction of catalytic activity requires the 
achievement of minimal time- and concentration-dependent thresholds in order for PAC-1 to 
activate procaspase-3.  Because high concentrations of PAC-1 are associated with neuronal 
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hyperexcitation, viable therapeutic strategies necessitate the institution of low, but temporally 
sustained (48 hours) PAC-1 dosing protocols.  This requirement will likely impact the 
therapeutic institution of PAC-1 clinically.  Dogs would either need to be hospitalized for 48 
hours for constant rate infusion of PAC-1 or a bone-targeted delivery strategy would need to be 
developed to prolong residence of the PAC-1 within the bone tumor microenvironment. 
Given the observed processing of procaspase-3 to caspase-3 in conjunction with the 
identification of increased caspase-3 enzymatic activity induced by PAC-1 at 48 hours, we 
sought to determine if procaspase-3 activation by PAC-1 would result in cell death via induction 
of apoptosis in the HMPOS cell line.  When cells were incubated with PAC-1 for 48 hours, a clear 
dose dependent effect was observed.  A dramatic decrease in viability was noted at the 10 µM 
concentration confirming the significant and strong proapoptotic effects of PAC-1 at this 
concentration.  Notably, the loss of cell viability at 10 µM was accompanied by nearly all 
HMPOS cell staining positively for Annexin V FITC and negatively for propidium iodide.  The 
appearance of nearly all of the cells within the Annexin V FITC gate suggests that the major 
mechanism of cell death for PAC-1 is apoptosis, not necrosis.  A small but significant increase in 
apoptotic cells was also observed at the 3 µM concentration, but there was almost no effect at 
concentrations at or below 1 µM. 
 In summary, the present findings indicate that procaspase-3 is expressed in canine OS 
cells and that the target is conserved among the species investigated.  When OS cells were 
exposed to low, biologically relevant concentrations of PAC-1, conversion of procaspase-3 to 
active caspase-3 was observed.  Furthermore, PAC-1 induced caspase-3 catalytic activity and 
apoptosis in canine HMPOS cells, a finding which was most pronounced after 48 hours of 
exposure to PAC-1.  Based on these results, further investigations of the use of PAC-1 as a 
treatment for canine OS are warranted.  Future studies should focus on delivery strategies that 
would allow for prolonged exposure of the bone tumor microenvironment to PAC-1 in vivo. 
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3.5 Figures 
 
 
FIGURE 3.1: Procaspase-3 is expressed by human, canine, and murine osteosarcoma cell lines.  Lane 1 
represents MCF7, a human negative control.  Lanes 2-3 are human osteosarcoma cell lines, 4-7 are 
canine osteosarcoma cell lines, and 8-9 are murine osteosarcoma cell lines.  Note the band appearing at 
the characteristic molecular weight for procaspase-3 for all cell lines, and the double band for all canine 
cell lines. 
49 
 
 
FIGURE 3.2: Procaspase-3 target is modulated by PAC-1 in human, murine, and canine osteosarcoma cell 
lines.  Human: The 143B osteosarcoma cell line was incubated with vehicle control (VC) media, or PAC-1 
at 10 µM for 12, 24, and 48 hours. A time dependent decrease was seen in the band intensity of 
procaspase-3 at this dose.  The fully processed 17 kDa (large fragment) of cleaved caspase-3 peaked at 
24 hours and then declined again at 48 hours.  Murine: The K7M2 osteosarcoma cell line was treated as 
described for 143B.  A similar trend was seen with a dose dependent decrease in procaspase-3 and a 
peak in the large fragment of cleaved caspase-3 at 24 hours.  Canine: The HMPOS osteosarcoma cell line 
was incubated with vehicle control (VC) media or 3 or 10 µM PAC-1 for 24 and 48 hours.  A small 
decrease in procaspase-3 and an increase the large fragment of cleaved caspase-3 was seen at 24 hours 
for the 10 µM dose and 48 hours for both the 3 and 10 µM doses.   
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FIGURE 3.3: PAC-1 at 10 µM concentration is capable of promoting procaspase-3 activation to 
enzymatically-active caspase-3 in HMPOS cells after 48 hours of exposure, but no difference in caspase-3 
activity is detected between vehicle or PAC-1 treated cells at shorter incubation times (24 hours). 
 
 
FIGURE 3.4: Flow cytometry of HMPOS cells exposed to varying concentrations of PAC-1 (1-10 µM) for 
48 hours.  Dot plots demonstrate that viable cells are retained in the lower left hand quadrant, and early 
apoptotic cells shift to the lower right hand quadrant.  Significant decrease in cell viability observed with 
HMPOS cells are exposed to PAC-1 at 10 µM.  A significant increase in early apoptotic cells is identified 
when HMPOS cells are incubated with PAC-1 at 3 and 10 µM for 48 hours.  Significance defined as 
p<0.05. 
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Figure 3.5: Bar graph represents PAC-1’s concentration dependent properties for reducing HMPOS cell 
viability.  Significant reduction in cell viability exerted by PAC-1 at 10 µM for 48 hours, *** p<0.001. 
 
 
Figure 3.6: Bar graph represents PAC-1’s concentration dependent pro-apoptotic effects in HMPOS cells 
exposed to PAC-1 for 48 hours.  Significant increase in early apoptotic cells following exposure to PAC-1 
at both 3 and 10 µM for 48 hours; *p<0.05 and **p<0.01. 
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CHAPTER 4 
DIFFERENTIAL EXPRESSION OF PROCASPASE-3 IN CANINE OSTEOBLASTS AND CANINE 
OSTEOSARCOMA 
 
4.1  Introduction 
 Apoptosis is a crucial physiologic process important for normal cellular differentiation 
and development [1-4] and is characterized morphologically by cell shrinkage, cytoplasmic 
membrane blebbing, nuclear fragmentation and condensation, and DNA cleavage [5].  
Dysregulated apoptosis contributes to the development of many diseases, including 
neurodegenerative disorders, autoimmune diseases, and is widely recognized as one of the 
hallmarks of tumor development [1, 3-7].  Apoptotic cell death is triggered by a variety of 
cellular stresses which tumor cells endure both during the process of oncogenesis and as a 
result of anti-cancer therapy [348].  It entails a complex cascade of proteolytic events that 
involves a family of aspartic-specific cysteine proteases called caspases as well as the activators 
and inhibitors of these of these proteases [34, 73, 166].   
Active caspases are generated by successive cleavage of their zymogen or pro-forms, 
which occurs following delivery of an apoptotic signal to the cell.  Initiation of the cascade can 
occur either through the ligation of death receptors of the tumor necrosis factor (TNF) receptor 
family and formation of the death inducing signaling complex (DISC; extrinsic pathway) or 
following the induction of mitochondrial outer membrane permeability (MOMP; intrinsic 
pathway) by Bcl-2 family members [1, 2]. All caspase dependent pathways ultimately converge 
on the activation of a common executioner caspase, procaspase-3, a downstream and crucial 
event that leads to cleavage of hundreds cellular substrates and cellular dismantling [128, 129, 
131].  The active form of caspase-3 is generated after cleavage of the procaspase-3 at specific 
aspartic acid residues to generate two subunits with a molecular mass of 17 and 12 kDa which 
associate with each other to form active caspase-3 [32]. 
Since both intrinsic and extrinsic apoptotic pathways lead to the activation of caspase-3, 
any upstream disruption in apoptosis causing inefficient effector caspase activation may be 
hypothesized to lead to increased concentrations of procaspase-3 within tumor cells.  
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Investigations have shown that certain human cancer cell lines have elevated procaspase-3 
concentrations when compared with noncancerous controls, including lung, melanoma, renal 
and breast cancer cell lines [198].  In addition, tumor samples from individuals with 
spontaneously occurring neuroblastomas [200], lymphomas [201], leukemias [202], 
hepatocellular carcinomas [203], and melanomas [204] have been demonstrated to have 
procaspase-3 elevation.  In a recent study of canine lymphoma, it was also shown that canine 
lymphoma cells expressed procaspase-3 and that those with a higher degree of expression 
were more susceptible to a procaspase activating drug (PAC-1) [211]. 
To the author’s knowledge, the relative expression of procaspase-3 has not been 
studied in canine primary and metastatic osteosarcoma (OS).  Therefore, the objective of this 
investigation was to characterize the expression of procaspase-3 in canine OS cell lines, as well 
as non-malignant primary canine osteoblasts, and spontaneously occurring primary and 
metastatic canine OS tumor samples.  The study hypothesis was that canine OS cells would 
have greater procaspase-3 expression than normal canine osteoblasts and that procaspase-3 
would be expressed to varying degrees in spontaneous canine OS.   
 
4.2  Materials and Methods 
4.2.1 Cell lines 
Six canine OS cell lines (HMPOS, POS, Abrams, Cos31, D17, and Molly) were utilized for 
procaspase-3 quantification.  Three non-malignant primary canine osteoblast cell lines were 
either purchased or generated de novo, including the OB934 canine osteoblast cell line 
provided by William Kisseberth (The Ohio State University), CnOB a commercially-available 
canine osteoblast cell line (Cell Applications San Diego, CA), and UIUCOB2 generated at the 
University of Illinois from canine trabecular bone as described below.  All cell lines were 
maintained in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% fetal 
bovine serum (FBS), penicillin, streptomycin and plasmocin (Invitrogen, Carlsbad, CA).    All 
adherent cell cultures were grown in cell culture plates (Corning, Inc., Corning, NY) and were 
maintained at 37oC in 5% CO2 and passaged twice weekly or more frequently if needed to 
maintain cell viability.  When needed for experimentation, cells were harvested and counted 
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with a hemacytometer.  A trypan blue dye exclusion test was performed before each use to 
check for viability (Hazleton Research Products, Denver, PA). 
 
4.2.2 Reagents and Antibodies 
A monoclonal rabbit anti-caspase-3 (8G10) antibody (Cell Signaling Technology, Danvers, 
MA), which binds both the full length and large fragment (p19/17) of caspase-3, was used as a 
primary antibody for western blotting.  As a secondary antibody, a donkey anti-rabbit IgG:HRP 
antibody (GE Healthcare Amersham Piscataway, NJ) was used in conjunction with a 
commercially-available ECL kit. 
    
4.2.3 Canine osteoblast isolation 
Trabecular bone samples were harvested under sterile conditions from canine proximal 
humeri within 12 hours of death or amputation using an 8-11 gauge Jamshidi biopsy needle.  
The forelimb was clipped and prepped, a skin incision was made, and the muscle and fascia was 
sharply dissected to expose bone.  Using the Jamshidi needle, trabecular bone samples were 
obtained and placed directly into DMEM supplemented with 10% fetal bovine serum, penicillin, 
and streptomycin.  Following harvest, the bone was cut into 1-2 mm3 pieces using a sterile 
scalpel blade (#10) and washed once in PBS.  Bone pieces were then incubated for 1 hour in 4 
mL of collagenase solution (2 mg of collagenase/mL of sterile filtered DMEM) at 37°C in a 
shaking incubator to remove soft tissue.  After 1 hour, the solution was shaken vigorously by 
hand and then incubated an additional hour.  Then, 4 mL of complete culture medium (cCM- 
DMEM with 10% FBS, 1% Penicillin/ Streptomycin) was added to inhibit collagenase, and the 
bone fragments were rinsed three times with cCM.  Approximately twenty bone pieces were 
then transferred to a 100 mm dish and incubated in cCM.  Media was changed three times per 
week until osteoblasts migrated off of the bone fragments and onto the dish (about 1 week).  
Once cells migrated onto the dish, media was replaced with osteoblast differentiation medium 
(DMEM with 10% FBS, 1% Penicillin/ Streptomycin, 0.2 mM ascorbic acid, 10 mM beta-glycerol 
phosphate, and 1 µM dexamethasone) and changed three times per week until harvest. 
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4.2.4 In vitro analysis of differential expression between canine normal osteoblasts and 
osteosarcoma 
Western blot was performed for detection of the target, procaspase-3, in canine normal 
osteoblast and OS cell lines.   After incubation, cells were harvested from cell culture at 60-70% 
confluence.  Media was discarded; cells were washed once in neutral phosphate buffered saline 
(PBS) and incubated with 1 ml 0.25% Trypsin (Thermo Scientific, Logan, UT) for 5 minutes.  
Fresh medium was added and cell suspensions were collected in conical tubes, centrifuged, and 
washed once with neutral PBS.  For protein extraction, cells were re-pelleted, incubated with an 
appropriate quantity of Mammalian Protein Extraction Reagent (M-PER, Thermo Scientific, 
Rockford, IL) and protease inhibitor cocktail (Thermo Scientific, Rockford, IL) (100:1) and shaken 
at room temperature for 15 minutes.  Following incubation, cell lysates were centrifuged and 
the supernatant was collected.  Protein quantification was determined using the Pierce BCA 
Protein Assay kit (Thermo Scientific, Rockford, IL) according to the manufacturer’s instructions.   
For analysis by SDS-PAGE electrophoresis, 50 µg of protein from each sample was boiled 
in Laemmli’s sample buffer with 2-mercaptoethanol reduction at 95˚C for 5 minutes.  The 
samples were then briefly placed on ice and loaded in 4–15% Mini-PROTEAN® TGX™ Precast 
polyacrylamide gels (BioRad Hercules, CA ) in SDS-PAGE electrophoresis buffer.  Precision Plus 
Protein™ WesternC™ (BioRad Hercules, CA ) was used for the protein standard, and gels were 
run at 80V until completion.  Proteins were then transferred to the membrane using the Mini 
Trans-Blot (BioRad Hercules, CA ) at 53V for 45 minutes.  For detection of procaspase-3 protein, 
the membrane was blocked in 5% milk (in TBS-T) for 1 hour, washed three times with TBS-T, 
and then incubated with the primary antibody at a 1:500 dilution at room temperature for 1 
hour.  The membrane was then washed and incubated with secondary antibody at a 1:1000 
dilution for 1 hour and developed.   Membranes were stripped and reprobed for β-actin.  Band 
intensities for procaspase-3 and β-actin were determined by measuring the number of pixels/ 
mm2 and subsequently expressed as a ratio (procaspase-3/β-actin) to allow for quantitative 
comparisons among different cell lines. 
  
4.2.5 Immunohistochemical detection of Procaspase-3 in primary and metastatic OSA tissue 
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Tissue sections were created from archival material of primary appendicular OS (n=20) 
and metastatic OS (n=6).  Formalin fixed, decalcified, paraffin-embedded tissues were sectioned 
3-5 microns thick and captured on charged slides using routine methods.   Hematoxylin and 
eosin (HE) stained slides were used to confirm the diagnosis of OS in all cases. 
Immunohistochemistry (IHC) for procaspase-3 was performed using a rabbit monoclonal 
antibody (E61; Epitomics, Burlingame, CA).  Heat-induced epitope retrieval was performed 
using an automated pressure cooker in citrate buffer (pH 6.0).  Endogenous peroxidases were 
blocked using 3% hydrogen peroxide applied to all tissue sections for 10 minutes.  Primary 
antibody was applied at a 1:1000 dilution and immunodetection was performed utilizing Dako 
Envision+Rabbit polymer and a Dako Autostainer (Dako Corporation, Carpinteria, CA) staining 
system.  Visualization of antibody binding was obtained via DAB+ chromogen, (a 3, 3-
diaminobenzidine solution) for 5 minutes; tissue section counterstaining was performed using 
hematoxylin for 5 minutes, followed by progressive alcoholic dehydration and placement of a 
coverslip.  Normal canine lymph node and human tonsil were utilized as positive controls, while 
commercially available rabbit non-immune serum (Biogenex) was used as a negative control for 
each experiment.  
All slides were evaluated by one pathologist (LB) using light microscopy to assess for 
specific labeling of neoplastic osteoblasts.  Each section was scored for labeling intensity 
(1=light, 2=moderate and 3=intense) and the percent of labeled neoplastic cells was estimated.  
Tumor samples were assigned numbers according to the patient from which they were derived. 
All primary OS tumor samples derived from bone and all metastatic OS tumor samples were 
derived from lung tissue. In all patients which metastatic tumors were evaluated, a primary 
tumor from the same patient was also available for review.   A semi-quantitative 
immunohistochemical (IHC) method was used to determine the level of procaspase-3 
expression.  The intensity of procaspase-3 staining was scored from 0 to 3, and the extent of 
staining scored from 1 to 4 (0-24%-1, 25-49%-2, 50-74%-3, 75-100%-4). The scores were then 
multiplied together and the final scores classified as follow: 0, negligible staining; 1–4, weak 
staining; 5-8, moderate staining; and 9–12, strong staining.  
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4.2.6 Statistical analysis 
Differences in procaspase-3/β-actin ratio between normal (n=3) and malignant 
osteoblast (n=6) cell lines were evaluated with a non-parametric Wilcoxon-rank sum test.  
Significance was defined as p<0.05. 
 
4.3  Results 
4.3.1 Procaspase-3 is differentially expressed in canine osteoblasts and canine 
osteosarcoma cell lines 
Immunoblotting analysis showed that the canine (HMPOS, POS, Abrams, D17, COS31, 
and Molly) OS cell lines and normal canine osteoblasts express procaspase-3 as evidenced by a 
35 kDa band (Figure 4.1 A).  When normalized to β-actin as a ratio, the median band intensity 
(pixel value/area) for malignant osteoblasts (0.97; range 0.94-1.2) was significantly greater than 
the median band intensity for normal osteoblasts, (0.27; range 0.19-0.73) (Figure 4.1 B). 
 
4.3.2 Procaspase-3 is expressed in primary and metastatic spontaneously occurring canine 
osteosarcoma 
Twenty primary OS and six metastatic OS samples were analyzed.  Among the samples 
analyzed, 73% demonstrated negligible (11%) or weak (62%) procaspase-3 expression and 27% 
showed moderate (23%) or strong (4%) procaspase-3 expression (Table 1).  Typical examples 
are shown in Figure 4.2.  Overall, 90% of primary and 86% of metastatic tumors demonstrated 
some degree of positive procaspase-3 immunostaining.  Of these, 25% of primary tumors and 
42% of metastatic tumors had moderate or strong procaspase-3 immunoreactivity.  Notably, 
paired primary and metastatic tumors derived from the same patient tended to have similar 
procaspase-3 immunoreactivity, suggesting that procaspase-3 expression does not serve as a 
selective pressure during metastatic OS progression.  Most importantly, there was wide 
variability among different OS specimens regarding their respective procaspase-3 
immunoreactivity, indicating that tumors derived some patients may be more suitable for 
procaspase-3 activating therapies than others (Figure 4.3). 
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4.4  Discussion 
 The present study demonstrated differential expression between canine OS cell lines 
and normal canine osteoblasts and confirmed the expression of procaspase-3 in canine 
spontaneously- occurring primary and metastatic OS tissue samples. 
To determine if canine OS cells may be more susceptible to procaspase activating 
therapies than normal canine osteoblasts, we investigated the differential expression between 
normal and malignant osteoblasts.  Our results indicate that while normal and malignant 
osteoblasts express procaspase-3 by western blot analysis, the median band intensity for 
malignant osteoblasts was significantly greater than that for normal osteoblasts.  This data 
corresponds with previous studies that have demonstrated a difference between normal and 
malignant cells.  For example Putt et al. found that resected colon tumors had elevated 
procaspase-3 concentrations when compared with adjacent non-cancerous colon tissue from 
the same patient in all cases [208].  Additionally, investigations have revealed that some human 
cancer cell lines have elevated procaspase-3 concentrations when compared with 
noncancerous controls, including lung, melanoma, renal and breast cancer cell lines [198].  
Preferential expression of procaspase-3 in OS cell lines over normal osteoblasts may allow 
selective targeting of cancerous osteoblasts with procaspase activating therapies, thereby 
minimizing off-target effects to normal bone. 
 To the author’s knowledge, this is the first report to specifically characterize the pattern 
and relative expression levels of procaspase-3 in primary and metastatic canine OS.  A recent 
study evaluating immunohistochemical expression of several apoptosis regulators in canine 
appendicular OS found diffuse procaspase-3 cytoplasmic staining in all cases (100%) but 
differences in expression among tumors were not reported [349].  Our data agree with this 
report in that a high proportion of primary (90%) and metastatic (86%) tumors stained 
positively for procaspase-3 via immunohistochemistry.  However, the present findings indicate 
a wide variability in procaspase-3 expression among tumor samples.  This variability suggests 
that PAC-1 treatment might be more suitable and effective for dogs whose tumors express 
aberrantly high levels of procaspase-3 and less so for patients with lower expressing 
procaspase-3 tumors.  Therefore, in order for PAC-1 to be rationally implemented as an 
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anticancer agent in canine OS, the authors recommend the prescreening of OS biopsy samples 
for relative procaspase-3 expression and subsequent rationale institution of PAC-1 centric 
therapies for patients with highest procaspase-3 expression.  This recommended assertion is 
also supported by the findings of Putt et al. which indicate that assessment of procaspase-3 
concentrations in cancer biopsies is simple and rapid and can be used to predict PAC-1 efficacy 
[208].  Our conclusions emphasize the concept of personalized cancer medicine, where only the 
dogs that are most likely to benefit from the drug would be treated with a procaspase-3 
activating strategy. 
 Another interesting finding is that when primary OS lesions were paired with metastatic 
lesions derived from the same patient, paired tumors shared the same pattern of procaspase-3 
expression with respect to overall percent positivity and staining intensity.  This suggests that 
the procaspase-3 genotype is conserved between primary and metastatic cells, and there does 
not appear to be downregulation of the target following metastasis.  This finding lends 
justification for the use of PAC-1 for the treatment of both primary OS as well as metastatic 
lesions.  Although a trend was subjectively identified between primary and metastatic OS 
lesions with regards to procaspase-3 expression, strong conclusions cannot be stated as the 
current study only evaluated a limited number of metastatic tumors (n=6).  Future 
investigations should seek to determine if this pattern of conserved procaspase-3 expression is 
consistent in a larger number of paired primary and metastatic samples. 
 In summary, the data presented herein indicate that canine malignant osteoblasts have 
higher levels of procaspase-3 expressions than normal osteoblasts and suggest a theoretical 
selectivity of procaspase-3 activating strategies for malignant cells.  Furthermore, procaspase-3 
is variably expressed in canine OS samples and the degree of expression appears to be 
conserved between paired primary and metastatic lesions derived from the same patient.  
These study results underscore procaspase-3 as a viable drugable target in canine OS and lends 
justification for the use of PAC-1 as a personalized anticancer strategy, especially in OS lesions 
demonstrating robust procaspase-3 expressions.    
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4.5 Figures 
 
 
Figure 4.1: A) Both malignant and normal osteoblasts express procaspase-3. Western blot was 
performed on canine osteosarcoma and normal osteoblast cell lines, and revealed a band at the 
characteristic molecular weight for procaspase-3 (35 kDa).  B) The pixel value/area was normalized to β-
actin (ratio).  The median band intensity ratio (procaspase-3/β-actin) was found to be significantly 
greater for malignant than normal canine osteoblasts, p=0.02. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* 
A B 
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Table 1: Relative procaspase-3 immunoreactivity in primary and metastatic OS lesions 
Primary 
OSA Sample 
Intensity  % Staining  Score Metastatic 
OSA Sample 
Intensity % Staining Score 
1 1 15 1 1 1 20 1 
2 1 5 1     
3 1 80 4 3 1 90 4 
4 1 25 2 4 0 0 0 
5 1 10 1 5 1 10 1 
6 2 85 8 6 2 85 8 
7 2 85 8 7 2 85 8 
8 1 50 3     
9 1 95 4     
10 1 15 1     
11 2 15 2     
12 2 25 2     
13 3 85 12     
14 1 15 1     
15 2 95 8     
16 1 15 1     
17 2 90 8     
18 0 0 0     
19 0 0 0     
20 1 5 1     
 
TABLE 1:  Procaspase-3 immunoreactivity scores for spontaneously occurring primary and metastatic 
osteosarcoma samples by patient number. Note that patients 1-5 have both primary and metastatic 
tumors that are scored as weakly immunoreactive while patients 6 and 7 have both primary and 
metastatic tumors that are scored as moderately immunoreactive.  
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Figure 4.2: Graduation of staining canine osteosarcoma tumor samples.  A. Weak staining for 
procaspase-3 (score 1-4). B. Moderate staining for procaspase-3 (scores 5-8). C. Strong staining for 
procaspase-3 (scores 9-12).  
 Primary              Metastases 
Low 
Intermediate 
High 
A 
B 
C 
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Figure 4.3: Paired OSA primary and lung metastases samples.  Primary and metastases #3 display weak 
immunoreactivity for procaspase-3; whereas primary and metastases #7 display moderate 
immunoreactivity for procaspase-3.  Overall, 90% of primary tumors were positive for procaspase-3 
staining whereas 86% of metastatic tumors were positive for procaspase-3 staining. 
 
  
#3 
#7 
Primary 18/20 (90%) 
Metastases 6/7 (86%) 
Paired Samples 
Primary       Metastases 
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CHAPTER 5  
CONCLUSIONS 
 
Procaspase-3 is expressed in osteosarcoma (OS) cells and the target is conserved across 
species.  It is possible that there is a decreased degree of procaspase-3 expression in canine OS 
lines in comparison with other immortalized OS cell lines derived from both human and murine 
origin.  However, further investigation is needed to determine if this is a true finding or related 
to differences in antibody cross-reactivity.  If this is a true difference, it may indicate that 
procaspase-3 activating strategies will be more effective for human OS than canine OS.  
Additionally, exposure of OD cells to biologically relevant concentrations of PAC-1 (10 µM) in 
vitro results in a dose- and time- dependent conversion of the target procaspase-3 to active 
caspase-3.  This is accompanied by an increase in catalytic activity of caspase-3 and significant 
cell death by apoptosis at the 48 hour time point.  These findings support further studies 
investigating the therapeutic application of PAC-1 in canine OS.  Such investigations should 
focus on using a delivery strategy that results in at least 48 hours of bone tumor exposure to 
PAC-1.   
Procaspase-3 is expressed to a significantly greater extent in malignant versus normal 
canine osteoblasts.  This is clinically important because it suggests that procaspase-3 activating 
strategies would be selective for malignant cells.  In the case of OS, this could result in 
decreased off-target effects to normal bone, minimizing the risk of decreased bone strength or 
fracture following treatment.  Additionally, procaspase-3 is expressed in a high percentage of 
spontaneously-occurring primary and metastatic OS.  However, inter-patient variability of 
procaspase-3 expression is wide and pretreatment biopsies with procaspase-3 screening would 
be recommended for optimizing the rational therapeutic institution of PAC-1 in vivo.  Notably, 
primary and metastatic tumors derived from the same patient trended to have a conserved 
pattern of expression suggesting that procaspase-3 is not downregulated during metastatic OS 
progression, and thereby might provide a conserved drugable target for managing both primary 
and metastatic OS lesions.   
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The results derived from the current investigation supports future study of targeted 
procaspase-3 activating strategies for the treatment of OS.  Forthcoming investigations should 
focus on demonstrating a therapeutic response in dogs with OS and determining if that 
response is greater in dogs with higher levels of procaspase-3 expression.  Ideally, a specialized 
delivery strategy would be used that prolongs PAC-1 exposure, yet minimize the likelihood for 
off-target toxicity including neuronal hyperexcitation.  For the management of primary bone OS 
lesions, this may be best achieved by bone seeking strategies such as direct conjugation to a 
bisphosphonate or encapsulation in a bone seeking nanoparticle.  For metastases, increased 
duration of exposure may be achieved by constant rate infusion intravenously or by delivery of 
PAC-1 as an inhalation therapeutic.   Although the current investigation focuses on the 
justification of PAC-1 as a single agent for treatment OS, additional future studies are planned 
to assess the ability of PAC-1 to synergize with conventional cytotoxic agents; thereby 
broadening the potential therapeutic applications of procaspase-3 activating compounds for 
the management of cancer. 
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